<SEC-DOCUMENT>0001193125-15-075849.txt : 20150304
<SEC-HEADER>0001193125-15-075849.hdr.sgml : 20150304
<ACCEPTANCE-DATETIME>20150304064431
ACCESSION NUMBER:		0001193125-15-075849
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20150304
FILED AS OF DATE:		20150304
DATE AS OF CHANGE:		20150304

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVOGEN LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		15671751

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		LEVEL 1
		STREET 2:		16 - 20  EDGEWORTH DAVID AVE
		CITY:			HORNSBY NSW
		STATE:			C3
		ZIP:			2077
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d884256d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of March, 2015 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Novogen
Limited </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form 40-F&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7):&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Note</B>: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant&#146;s &#147;home country&#148;), or under the rules of the home country exchange on which the registrant&#146;s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant&#146;s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#254;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;yes&#148; is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b) </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Novogen Limited </B>(Registrant) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Lionel Mateo </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lionel Mateo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Company Secretary </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date 4 March 2015 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g884256001.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="29%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="55%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX:NRT</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NASDAQ:NVGN</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Ltd</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(Company)</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ABN 37 063 259 754</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Capital Structure</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinary Shares on issue:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">250 M</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Board of
Directors</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dr Graham Kelly</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chairman &amp; Executive Director</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Steve Coffey</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>John O&#146;Connor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prof Peter Gunning</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Non Executive Director</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX RELEASE</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4&nbsp;March
2015</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>US STUDIES CONFIRM ABILITY OF TRXE-009</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO KILL BRAIN CANCER STEM CELLS</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;Potent killing of highly resistant adult and pediatric brain cancer cells</B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.50em; font-size:10pt; font-family:Times New Roman"><B>&#149;&nbsp;&nbsp;&nbsp;&nbsp;Opportunity to
effect prevention of recurrence of brain cancer</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>4&nbsp;March 2015, Sydney,
Australia:</B> Novogen Limited (ASX:<I>NRT</I>; NASDAQ:<I>NVGN</I>): Australian/US biotechnology company, Novogen Limited, today announces that it has confirmed that one of its lead candidate products, TRXE-009, is showing the potential to become an
important new therapy in the fight against adult and pediatric brain cancer.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
latest study looked at the ability of TRXE-009 to kill a library of patient-derived cell cultures from subjects with glioblastoma multiform (GBM). The cells were cultured under conditions that promote cancer stem cell growth. These stem-like cancer
cells are believed to be responsible for chemotherapy resistance and tumor recurrence.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Killing these highly-resistant GBM cancer stem cells is considered to be a fundamental requirement to successfully treating this highly destructive
disease.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All patient derived cancer cells represented in the library responded to
TRXE-009 at clinically relevant doses, suggesting a strong therapeutic potential.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
studies were conducted by Drs John Boockvar and Marc Symons at the Feinstein Institute for Medical Research (Feinstein) and with which Novogen is forging a strong collaboration to oversee advancing TRXE-009 into the clinic for adult and pediatric
brain cancers.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These findings join with other recently announced pre-clinical studies
showing that TRXE-009 is highly cytotoxic of chemo-resistant pediatric brain cancers such as Diffuse Intrinsic Pontine Glioma (DIPG) as well as other pediatric neural and neural crest-derived tumors (i.e. medulloblastoma and neuroblastoma,
respectively). Together, these studies suggest that TRXE-009 is a unique drug candidate in preferentially targeting tumors with a common embryonic origin in neural/neural crest cells.</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The next step in this drug&#146;s development is to confirm it&#146;s ability to cross the
blood-brain barrier, a key filtering mechanism that effectively blocks the majority of chemotherapic drugs from reaching brain tissue.</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">TRXE-009 was designed to cross the blood-brain barrier and has been formulated as a proprietary drug product known as Trilexium. It is anticipated that
Trilexium will have application in the treatment of cancers both with and without brain involvement. Trilexium is due to enter a Phase 1 study in early-2016.</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g884256003.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In conjunction with Feinstein, alternative means of delivering TRXE-009 to the brain are under investigation including
direct injection into the brain cancer by the process known as convection-enhanced delivery, and the use of lipid brain-targeting particles injected intravenously. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr Graham Kelly, Novogen Group CEO, said, &#147;TRXE-009 has been a drug development success story, thanks to a team led by Andrew Heaton PhD and Eleanor Ager,
PhD. The TRXE-009 story started with the discovery of a compound that was highly cytotoxic against GBM brain cells that came from patients who had failed to respond to Temozolomide, the only standard of care chemotherapy for GBM; it then showed
itself to be an equally effective killer of GBM cancer stem cells; it also is highly active in vitro against a range of pediatric brain cancer cells that are notoriously resistant o chemotherapy; it has been designed to cross the blood-brain
barrier; it shows little toxicity against normal human brain cells (astrocytes) in vitro; in its parenteral delivery form, the Trilexium drug-product is highly active in animal models of xenografted human tumors, including GBM, and is reasonably
well tolerated. So far it has ticked every box asked of it.&#148; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The urgent need to find a successful treatment for devastating cancers such as
primary and secondary brain cancers in adults and children is what is driving our collaboration with Feinstein to bring TRXE-009 into the clinic,&#148; Kelly added. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Novogen Limited </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen is a public, Australian
drug-development company whose shares trade on both the Australian Securities Exchange (&#145;NRT&#146;) and NASDAQ (&#145;NVGN&#146;). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been designed to kill the full
heterogeneity of cells within a tumor, including the cancer stem cells. The molecular target is a trans-membrane electron-transfer pump mechanism oncogene that is common to all cancer cells. Cells die by respiratory distress and mitochondrial
disintegration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ATM compounds target the micro-filament component of the cancer cell&#146;s cytoskeleton and have been designed to combine with
anti-microtubular drugs (taxanes, vinca alakaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company pipeline
comprises three SBP drug candidates (TRXE-002, TRXE-009, TRXE-0025) and one ATM drug candidate (&#145;Anisina&#146;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About TRXE-009 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TRXE-009 is an SBP compound generated by the Company&#146;s VAL-ID (Versatile Approach to Library-based Iterative Design) drug discovery process, with
structure-activity relationship driving design based on activity against brain cancer stem cells and the known required chemical criteria to facilitate passage across the blood-brain barrier. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Trilexium </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trilexium is the name give to a
proprietary parenteral formulation of TRXE-009 selected for its ability to maximize systemic drug delivery and effectiveness in pre-clinical rodent models of human cancer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information is available on our website <U>www.novogen.com</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g884256002.jpg" ALT="LOGO">
 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g884256003.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the Feinstein Institute of Medical Research </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Feinstein is the research entity of the North Shore-LIJ Health System, New York, one of the largest healthcare providers in the US and the largest integrated
health system in the State of New York. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">John Boockvar MD holds the following appointments: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Director, Brain Tumor and Pituitary/Neuroendocrine Center </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Department of Neurosurgery </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The New York Head and Neck Institute </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Lenox Hill Hospital/Manhattan Eye, Ear and Throat Hospital </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Investigator, Laboratory for Brain Tumor Biology and Therapy </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Center for Neuroscience and Oncology </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Director, Brain Tumor Biotech Center </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Feinstein Institute for Medical Research </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Professor of Neurosurgery and Otolaryngology/Head and Neck Surgery </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Department of Neurosurgery </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Hofstra-North Shore LIJ School of Medicine </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Marc Symons PhD holds the following appointments: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Investigator, The Feinstein Institute for Medical Research </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Co-Director, Brain Tumor Biotech Center, The Feinstein Institute for Medical Research </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Director, Light Microscopy Facility, The Feinstein Institute for Medical </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Professor, Department of Molecular Medicine and Department of Neurosurgery, Hofstra North Shore-LIJ School of Medicine </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information please contact: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Contact</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr. Graham Kelly</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Executive Chairman &amp; CEO</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Group</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Graham.Kelly@novogen.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+61 (0) 2 9472 4100</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Enquiries</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cristyn Humphreys</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Operating Officer</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Novogen Group</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Cristyn.Humphreys@novogen.com</U></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+61 (0) 2 9472
4111</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward Looking Statement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains &#147;forward-looking statements&#148; within the meaning of section 27A of the Securities Act of 1933 and section 21E of the
Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as &#147;expects,&#148; &#147;appear,&#148; &#147;intends,&#148; &#147;hopes,&#148; &#147;anticipates,&#148;
&#147;believes,&#148; &#147;could,&#148; &#147;should,&#148; &#147;would,&#148; &#147;may,&#148; &#147;target,&#148; &#147;evidences&#148; and &#147;estimates,&#148; and other similar expressions, but these words are not the exclusive means of
identifying such statements. Such statements include, but are not limited to any statements relating to the Company&#146;s drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the
Company&#146;s drug development program, including, but not limited to, TRXE-009, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties
relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company&#146;s drug components, including, but not limited to TRXE-009, the ability of the Company to procure additional
future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company&#146;s drug compounds, including, but not limited to, TRXE-009, that could slow or prevent products coming to market, the uncertainty of
patent protection for the Company&#146;s intellectual property or trade secrets, including, but not limited to, the intellectual property relating to [DRUG], and other risks detailed from time to time in the filings the Company makes with Securities
and Exchange Commission including its annual reports on Form 20-F and its reports on Form 6-K. Such statements are based on management&#146;s current expectations, but actual results may differ materially due to various factions including those
risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on those forward-looking statements as a prediction of actual future results. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g884256002.jpg" ALT="LOGO">
 </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g884256001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g884256001.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"`"4`LL#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]1;G4OL\S1^7NQCG=C^E1?VS_`-,1_P!]_P#UJK:G_P`?C_0?RJK0
M!I_VS_TQ'_??_P!:C^V?^F(_[[_^M6910!I_VS_TQ'_??_UJ/[9_Z8C_`+[_
M`/K5F44`:?\`;/\`TQ'_`'W_`/6H_MG_`*8C_OO_`.M6910!I_VS_P!,1_WW
M_P#6H_MG_IB/^^__`*U9E%`&G_;/_3$?]]__`%J/[9_Z8C_OO_ZU9E%`&G_;
M/_3$?]]__6H_MG_IB/\`OO\`^M6910!I_P!L_P#3$?\`??\`]:C^V?\`IB/^
M^_\`ZU9E*,9%`%AO$^&(^S=#_P`]?_K4G_"4?].P_P"_O_UJYR_OH+!6>ZD5
M,Y*@GEOH*Y;4_%$UR"ED&@C/4Y^8_P"%5&-S&K7A#=ZG>ZE\0[;3%(EMR\N,
MB-)<G\>.*RA\601D:5_Y-?\`V->>$DDDDDGKFDK3D1PSQ<V_=T/1?^%L_P#4
M*_\`)K_["C_A;/\`U"O_`":_^PKSJBCD1'UFKW_(]%_X6S_U"O\`R:_^PH_X
M6S_U"O\`R:_^PKSJBCD0?6:O?\CT7_A;/_4*_P#)K_["C_A;/_4*_P#)K_["
MO.J*.1!]9J]_R/1?^%L_]0K_`,FO_L*5/BPA=1+IC*A/)6XW$?AMKSFBCD0U
MB:O<]BM?&<-['OMH5=>^)>GZ5-_PE'_3L/\`O[_]:O';:ZFM)`]M(T;CNIZ_
M7UKI--\5(X6/40$;IYB_=/U]*B4+;'72Q49:2T9WW_"4?].P_P"_O_UJ/^$H
M_P"G8?\`?W_ZU8,;K*@>)E9&'!!SFEJ#KZ7-W_A*/^G8?]_?_K4?\)1_T[#_
M`+^__6K"HH`W?^$H_P"G8?\`?W_ZU'_"4?\`3L/^_O\`]:L*B@#=_P"$H_Z=
MA_W]_P#K4?\`"4?].P_[^_\`UJPJ*`-W_A*/^G8?]_?_`*U36_B#SRW^C[=H
M_P">F?Z5SE6]/ZR?04`;O]L_],1_WW_]:C^V?^F(_P"^_P#ZU9E%`&G_`&S_
M`-,1_P!]_P#UJ/[9_P"F(_[[_P#K5F44`:?]L_\`3$?]]_\`UJ/[9_Z8C_OO
M_P"M6910!I_VS_TQ'_??_P!:C^V?^F(_[[_^M6910!I_VS_TQ'_??_UJ/[9_
MZ8C_`+[_`/K5F44`:?\`;/\`TQ'_`'W_`/6H_MG_`*8C_OO_`.M6910!I_VS
M_P!,1_WW_P#6I#K849:(#_@?_P!:LN1_+7(&:K/(7.6H`V#XB':#/_`__K4?
M\)%_T[_^1/\`ZU8M%`&U_P`)%_T[_P#D3_ZU'_"1?].__D3_`.M6+10!M?\`
M"1?]._\`Y$_^M1_PD7_3O_Y$_P#K5BT>M`#-2^)']G7LMN=.\SR\?-]HQG(!
MZ;?>JW_"UO\`J%G_`,"O_L:Y3Q+_`,ANY_X!_P"@BLL^O:MHQ6AYE3$5%-I,
MZW5OC-=Z<IDM_#OVN(#+%-0PR_5?+_E6`/VE\D`>&R23@#^T>_\`W[J*VL);
MC!`")ZFEN/"]B-]Q#!&MV%XE"@%C5KV2T:.:I+&O6%2R]%_D=#I_QKN;N/?<
M^'OLJD94-J&6/U'EC%6_^%P_]0C_`,G/_L*\X)Z4E-TX=B%C*Z5G+\%_D>D?
M\+B_ZA/_`)-__84?\+B_ZA/_`)-__85YO11[.(_KM?\`F_(](_X7%_U"?_)O
M_P"PH_X7%_U"?_)O_P"PKS>BCV<0^NU_YOR/2/\`A<7_`%"?_)O_`.PH_P"%
MQ?\`4)_\F_\`["O-Z*/9Q#Z[7_F_(](_X7%_U"?_`";_`/L*HZC\;KJR7?!X
M<-S&!\VV_P`,/P\O^M<+2AJ:IP6Z%+%UVM)V^2_R-\?M,#OX<(_[B/\`]KH_
MX:87_H7?_*C_`/:JXS5/#]KJ8+%1%,>DBCK]1WKD=3\/76F$ET\R(?\`+1.G
MX^E;0I4I=#SJN.S"GKSW7HO\CV'_`(:87_H7?_*C_P#:J/\`AIA?^A=_\J/_
M`-JKPS'%&*OZM2['/_;&-_G_``7^1[G_`,-,+_T+O_E1_P#M5+_PTPO_`$+O
M_E1_^UUX7BN^\%_#@:M;0ZAK#LMK+\R01\,Z^I/8?3FIG1HQ5VC?#X_,:\^6
MG*[]%_D>A:3\?[W6[GR-,\*23-_$?[1PJCU)\K`%=U;^-9'A4W-@D<I'S(ES
MO`_':/Y5RUCI]MIELL&GP1P0KT5%Q^?K4]<<^1_"K'TV'A7BOWL[OT2.JB\6
M>:#_`*+C'_37_P"M4R^)03AK<J/7S,_TKF;3HWX5;K)[G4MCHAK8896($?[_
M`/\`6I?[9_Z8C_OO_P"M7.JQ1LJ<&K4-QYAVL,-_.D,V/[9_Z8C_`+[_`/K4
M?VS_`-,1_P!]_P#UJS**`-:#53/,J>5MW'&=^?Z5H5@V/_'W%_O5O4`8>I_\
M?C_0?RJK5K4_^/Q_H/Y55H`****`"BBB@`HHHH`****`"BBB@`I0,TG0<]JQ
M]3\3P6>4M?W\HZ[?NC\>]-)LF4HQ6KL:TLL<$9>9U1!U9C@5SNJ>*PKE-+&[
MG'FL/Y#_`!K"O-0N-1?==R,P!X4<*/H*@QCI6B@CSZV+E+2.B,RYN9+N9I+E
MVD<D\L<U%2GJ?K25?2QR!1110`4444`%%%%`!1110`4444`%%%%`BY8ZK<Z>
M3]GE(4]48Y!_"NIT[Q';7VU)3Y,Q_A)^4_0UQ5`XS[U+BF;TJ\H:'I=%<3IO
MB*YL"$D8SQ=-C'D#V/\`C75:?JUMJ2`V[X?',;<,*AP:/1IUX36^I<HHHJ#8
M****`"K>G]9/H*J5;T_K)]!0!:HHHH`****`"BBB@`HHHH`****`"BBB@!ES
M_JQ56K5S_JQ56@`HHHH`****`"@#)XHIK-@\4`<=K]N]QK=P(@3]S)QP/E%)
M;Z:D6#+\[>O85JZC_P`?LA/?'\A5:MNAYSI+F;`<#`IDOW&_W33Z9+]QO]TT
M%2V..-)2M25NMCQY;A1110(****`"BBB@`HHHH`*&PP(8`@]11136@&%JGA.
MWO`9+'_1YO3/R-^':N2O=.N-/EV7<;(W8GH?H:]*ID]O%=1&.XC1T/4,,U<*
MC3U.6KA(SU6C/+Z]]\%?\BII7_7LM>5ZIX-*AI-,?/<Q.?Y'_&O5O!T;1>&-
M-212K);JK`CH:6(:<4S?):,Z>(ES=OU-FBBBN0^H+5IT;\*MU4M.C?A5NLWN
M4M@J6V_UP^A_E452VW^N'T/\J0RW1110!8L?^/N+_>K>K!L?^/N+_>K>H`P]
M3_X_'^@_E56K6I_\?C_0?RJK0`4444`%%%%`!1110`4444`%+24HZT`<SXKU
M1PPL[<E1MW2D'KZ"N;"@=!6AXA_Y#MR!TPO_`*"*H5NMCQZ\W*;N%!.!D]J*
M#R#3,C(8;68'J#25<N;8G+)][J1ZU4((ZT`)1110`4444`%%%%`!1110`444
M4`%%%%`!1110`4Z.1HI`T;%64Y!'44VC&:!IV9WFB:E_:=BLCX\Q?E?'J/\`
M]=7ZYWP;Q#=#MN7_`-FKHJPEN>Q0ES4TP_$#ZFN0OOC#X"TR\GM-1\<>#[2Z
MMI6BG@GURVC>)U.&5E+Y!!!!!Y%97[0?C^]^&/P=\3>(]%@DGO[*V5+9E7<(
M))'6-9B/1"X<_P"[VZU^2$LTD\KRW#O)+(Q9W=LLS'J2>YS7#B\7[%I)79]W
MPKP@LWHSK5:CC%.RM;5[L_:RQOK;5+*"\TV>&ZM+J-98)X)`\<J,,JRL.""#
MD$<5I6`P9"?3%?)'_!/[XBW^O_#G6/#VMB3[+X4N(_LE[*0$$4^YO)+$]596
M/LKJ.,"OK:TO;-R(K:[MYI#D[4E5B?P%=5*I[2FIVW/E\XP7]G8^IA)R5XO[
MUNOO5BW1115G`%%%%`!1110`4444`%%%%`!1110`RY_U8JK5JY_U8JK0`444
M4`%(3BE'6FMUH`0\G-!Z44'I0!AZC_Q^2?A_(56JSJ/_`!^2?A_(56K7HCB>
M["F2_<;_`'33Z9+]QO\`=--$RV..:DI6I*W6QX\MPHHHH$%%%%`!1110`444
M4`%%%%`!1110`HKOM$&_2+;=S\@K@5ZUUOA[7(#;16MPPAD0;5+'AN>*BHKH
M[L%)*;N;+*5//3L:;4LH^7Z5%61ZY:M.C?A5NJEIT;\*MUF]REL%2VW^N'T/
M\JBS5BWB((=ACT%(98HHHH`L6/\`Q]Q?[U;U8-C_`,?<7^]6]0!AZG_Q^/\`
M0?RJK5K4_P#C\?Z#^55:`"BBB@`HHHH`****`"BE^E<]XC\;Z9X=0K/+Y]UV
MMXF!;_@1Z+347+1$5*D*<>:;LCH.N,<YZ4HZUX7K_CS5M>D(:<VMMGY88&*C
M\3G)_E[5=\.?$G4='V0WV[4+4'[KM^\0?[+=_H<UM]7E8\Y9O0YK.]NYUOB+
M_D/77T7_`-!%4*9-XCL?$.J7$VFS!C\H:)OE=?E'53SCWI]5RM+4PG.,I.47
M=!1112)#&:BFMEE'0`^HJ6B@#-FMVB'(R/45#FM=ER#[U7ELU;++P>X]:`*%
M%/>)HSAQBF4`%%%%`!1110`4444`%%%%`!1110`4444`=3X-_P!3<_[R_P#L
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MX&^-`I`/3`3/S*:\^\#>,K_X?>+--U_1&VW6FS"3;T$J='C/LRD@_6NI\/Z2
M_P`0?AW<V<]S:6=UX0G22RO;Z800FVN7.^W,C?+N$N)$!_O3>E3^#OA?!'K8
MO/$&HZ!JVG:7;S7]SI^F:M%//=K!&TGE*JG.&V88CHNX]J]_#TZ.&H>QZ1T]
M3\8SG&9EG6:O,FVY5&I)]O+Y-?J??-C\5?"EWI]E=7>OZ/IK7UK%<K;7M_%#
M-&LB*ZAT9@P.&'&*Z+3=5LM9L4O=(N[6^LY03'<6TRR1O@X.&4D'!!'7M7Y3
M:_KMYXFUN]U75I/,O+^=I9F`P,D]%'8`8`'8`#M7U%^Q!\0KUGUOP;=I-/9+
M;OJ%I*!D6Q!"R*3V#%E(]P?6O+Q64>RHNI&6W3^NQ]OD?';QV/CA*M.REHI*
M^_2ZZ7_`^L](UO3O$%I]JT#4++4[7<4\^SG69-PZC<I(R/2IK/4+748'FL+F
MWN88G>-Y(9`ZJZ$AU)'&0001V((-?-/[-[?\*XT_P/G,7AWXDZ1#R>4M]9AC
MQ_P'SXAZ\O%[U/IL9U[0/#_@^ZDFBTCQ7\0M?35?)<H;BW@N+R<V[,.0KLBA
ML<E=P[UXQ^CGNNF_$;PIK.KG2M(\3:!>ZF"1]C@U*)Y21U`0-DFMFTU&TOYK
MF*RNK>XELY/*N4BE#F%\`['`/RM@@X/."#7(^,?A)X6\4^#YM&.D:=IZ0PDZ
M?<6=ND+Z?*H_=RQ,N"I4@'@C..>*\K^!_BB\7QEX;U+66;;\4_"L-Q+*W_+7
M5;!1'*P'0>9`5?C^Y0!]`OJ5G'J$5A)=6R7T\;2Q6K2J)712`6"YR5!(&1QD
M@5BR?$KPC%K(TB7Q3X=352_E_8FU.$3;LXV[-V<Y[=:\*\::M<^(?$'C7Q!I
MUS/:QWFLZ9X!TZ^@?8]K`URGV^1#V8O*8PPZ&,>E>W-\*/!A\+_\(X?#.C'1
M?*\LVAM5QC&,[OO;^^_.[/.<T`=/<3Q6D#S7<D<,,2EGDD;:J@=22>U8>C?$
M'PMXBOFLM`\2:#J5ZO6WM-1BFD]_E5B:\(\((?'NI^$O`7B^>75=$\/SZX;I
M+H9&K?V?>);6BR_WU59=Q!R&903G%>^1Z)X;T.]T^2/3]$L+T%H-/9;>**0$
MH24BX!^XK9"]@>PH`JW7Q,\'V5U+;7GBOPU#<0.8Y8I-6@5D<'!5@6X((P0:
MUQKNFMJW]E)J%BVIB'S_`+$+A?.\O^_Y>=VWWQBO$/A=XETFUM=8M+[P;KVJ
M3GQ9K"M?VWA\W,)W:A-_RUQT7.#Z8/I6?\1]&O8/BYXM\9>&(VFUWP+IFC7\
M4"#FZM&^V"[MO^!Q98?[4:4`?0-UJ-J+M;$W-O\`;6B\X6_FKYGE@XW[<YVY
M(&<8S3:\RM=7M/$'QVT74](G6YL-1\`O<VTR])(WO(RI_(BO3:`"BBB@`'6F
MM]XTX=::WWC0`E!Z44'I0!AZC_Q^2?A_(56JSJ/_`!^2?A_(56K7HCB>["F2
M_<;_`'33Z9,0L3LQP%4Y-,F6QQS4E*:2MUL>.]PHHHH$%%%%`!1110`4444`
M%%%%`!1110`9Q1DT44`2W/B^[\.67FH!<P(Z@Q2$_=)&<'M71^'?&>F^)$Q9
MRF.XQEK>7`8?3L1]*\^\6?\`($E_WT_]"%<-&[1.KQLR.IRK*<$'U%:*C&<;
MF,LRJX>KR[KL?4%F<J_L16A'`TG^R/4UP/P6UV]U^UU-=6F-Q]C,2Q,X&0&W
MYR>_0=:]*["N"<>631]/AJ\:U)5([,9'"D62!DGN:?114FX4444`6+'_`(^X
MO]ZMZL&Q_P"/N+_>K>H`P]3_`./Q_H/Y55JUJ?\`Q^/]!_*JM`!1110`4444
M`%5=5U6VT6RDN]0D\N&/J0,DGL`.YJV.M<3\7?\`D6(O^OU/_07JHJ[2,,34
M=.C*:W1R_B7XHWVIEX-'#6%L<C?NS*X^O1?P_.N(8EV+.<L3DD\DTE%=ZBH[
M'R%7$5*KO-W"BBBF8',ZG/)::L\MK(\4B$%61L$<"NK\/_$N2,+!KR-*N?\`
MCXC'('^TO?\`#\JY#6_^0E+]1_Z"*HCK6W+&4=3&%>I2DW%GT#;SI<PI+`P>
M.10R..C`C(J2LSP;;2OX:T[Y=H-NN"W&:VS8R8RNT^V:X)*SL?2TTY13MN5Z
M*4JR$B0%3GO24AO3<****`$90PP<54FLN\9'TJY10!D$%3A@0?>DK4>!9!AN
M:J2V;+DIR/2@"M12D8-)0`4444`%%%%`!113D1I&PBD_TH`;4L<#2'Y>GK5F
M"R`YD.3Z5:`P.*`.@\$6RI#=MU(9>OT-=0.U<[X-_P!3>?[Z?UKHSUK&:]X]
M;#?PD0WMI!J-I/:WL2S6US&T<T3C*R(PP5/L037Q?KW["GB<ZW>_\(SK/AY=
M),[&R%Y<3B98B<JK@1$;@"!D$YQ7VK171AL95P]^3J>;G&08'->3ZU%OEO:S
MMN?G%\9_"-_\)+/2/`]XJLP3^U+^\BSY5].^Z-=A(!*1HI49`.YY#C#"O._#
MVO7OA;7+'5M&E\J]T^9986QD9!Z$=U(R".X)%?H9^T%\"X_C7H5A#:74.FZK
MI=P7M[N2,NIC<`21L!S@X4@]BN.YKR;X??L23^'?&.EZGXLUO3=4TW3YO/DL
MXK=U,[+RBG=QMW;21W`QWKV\/F5'V%ZCUZKN?EN:\&YDLSY<+!NGIRRNO=6F
M]]=#D+[]C'Q-XFN/[8\-76A:/I>JQQWEOIVHSSK-9"1`[0.%B8?(Q9.O(4$\
MU]!?L\?`\_!KPA>6^IS6EWKFJRE[RXMLF,(N1&BEE!*@$MT!RY]J]<Z#`&`*
M2O&KX^O6AR2>A^CY;PIEN`Q'UFE%\_=O37=I=#RFQ^#-Q<?`+2_`NLW-O#K.
ME6$0M+^U9BMK?0MOAF1BH;"R`=AD;AWJEH_P6UR7X=65AK.JV&F^,--\0W6O
M6>H::'GMX;F6>63;M<(SQLLS(R\<'J<<^QT5QGTAYGJVE_$_Q7I,^BZE_P`(
MCX<AO(C!>ZMIM_<74XC(PYMX7AC5'(S@L[;<YPV!3_'/PLN9O!WA:R^&C6%A
MJ_@:[M9]#^VLRQ%(U\IX9&56;:\3,#@')`KTFB@#S'1O@G!!\$;;P+JU](+S
MR1+<:G;/N=;_`,WSS<HQ`)(G^8$X)``/>I5?XLC3_L+0>`A>*OE_VT+RY8$=
M/-^R>2/GQSL\X+N[XKTFB@#RNZ^"<VD^'_"__""ZN;7Q-X1>XEM=1U!&F34&
MN#NNDN0#G;*YWG:<JP!7CBGW'ASQYXI\4^$+WQ;8^%-/M?#.J/>S2Z?JL]P]
MPS6TT&U(WMT"C,V>7.,=Z]1HH`\M\):!X^\$VFIV%AIO@N^L[C6;^^AFFUNY
MA?9<7,DP#(+1AD!\'YCTZ]ZZC2/"MY8?$CQ/X@N'MC9ZU8:=;P(K$NKVYN-^
MX%0,?OEQ@GOP*ZJB@#Q_X:_!G5_`'Q*O]0-WIDOA*WL+BST*UC9_M-M%/<+<
M>4X*A=B/YBJ0Q.-N:];D@S_J_P`JEHH`I$%3AA@T5=*AAAA5>2W9>5Y7U-`$
M0ZTUOO&GXP:8WWC0`E!Z44'I0!AZC_Q^2?A_(56J76+B.VN9&F8*!C^0KG+W
M77ERMH#&O]]NI_PK=1;2/.J58P;N:MYJ$-DO[QLOV0=36#?ZK+>`J/W<1_A7
MO]35-B6R222>22<YIM:*"1P5,0Y:=`HHHJC!NX4444""BBB@`HHHH`****`"
MBBB@`HHHH`****`,;Q;_`,@27_?3_P!"%<*.E=UXM_Y`DO\`OI_Z$*X4=*ZJ
M7PGD8W^+\O\`,]D_9]Y@UW_>M_\`VI7K/:O)?V??]1KO^];_`/M2O6NU>=7_
M`(C/KLJ_W2'S_,****Q/1"BBB@"Q8_\`'W%_O5O5@V/_`!]Q?[U;U`&'J?\`
MQ^/]!_*JM6M3_P"/Q_H/Y55H`****`"BBB@!1UKB?B[_`,BQ%_U^I_Z"]=L.
MM<3\73_Q3,7_`%^I_P"@O5T_B1RX[_=I^AX_1117H'Q@44^*&2XD"0J78]A6
M_I_AI0`^H$,?^>:GC\:3:1M2H3J/1'G]SI-SJVJS"SC+*&`9SPJ\#J:Z32?"
M-M8;9+K_`$F=>02/E7Z"NCNXTBF98E5%'0+P!Q_]:HAT-)U&]C>GA80=WJSM
M=*&-+M<8`"<`=JM56TO_`)!=M_N59KD;N?14_@0UXDE3;(`:IRV#1_ZK#`]N
MXJ]0#BBX3IJ1DY]>"*,UI36T=P/G^5O[PJA-:O">F5]157.65)IC**0$'H:6
M@R"BBB@"*6V249.0?451E@:(\\CU`K3I"@/6@#(HJ_+9J^=GRD56-K("1M)^
M@H`AI5&XX'6IX[-V^\"H_6KD4"Q#Y<Y]:`*L5D>LGY5;2%4&$&!3Z*`"BBB@
M#IO!O^IO/]]/ZUT9ZUSG@W_57G^^G]:Z,]:RGJSU\,OW*$HI<48J#8,=?;FD
M]?;K[50U_2;77-%N['4K:*\@FC),,@R&8<KQZ@@'->=_\(?J>G_!CP]IGAVV
M_L_6Q/HD]X#$6*2I<VQN))%5U+X57+#<,A3SSP`>J`%L8YR,C%)7DVI>'_%+
M^!?BO:Z@_P!NU;5&N#ILEG`\"SYTRVC3RD,CL/WBLOWN64GC-=OX!L$TWPW#
M;QV\-LR2.76'3)-/0L3G*PNS,.W))R030!T8&3@=?2C!':N$D\*WUS\89];D
MCLO[-M=*LXX'N+1I)#+NN]_DR"0",@-'NRC9!'3BLF?3M;/B;^SDL=3VCQ?'
MJHO,?Z.UDL"Y/F9P/G!3R_O9.=NWYJ`6IZA2XYQW%</<>";1_BM::R-,B:)=
M,FDDN]O'VL2Q>6W^_LWX/ID9[5D7EIK`\1W^EQ:9J;+>^*K+48+P+_HZV4<-
MOYF9"<#YX9%\O[Q+`X(;-`'IXY&1TH"E@"O.>F*\D\0>$-=G^*T&MVUNO]EQ
M7]BLDT43?:A&(Y`Q1]^/*WF-9$*G*L2#\HK7@T2X7XR7VHWMK'):O!"MG,^E
MRRL#Y3!RMP'V1C+-E2A))Z\T6`]$`)Z4F<G`ZUS?Q%LM1U#P=?0:"+F2Y=X&
MD@M9O)FN+=9T:>*-]R[7>$2H#N'+#D=1B>`M)>UU_6Y]$TR^T7PU/96RV]E=
M*T&^[4R^=*D)YC!5HE)P-[*6`XW,`=^.1D<BBN'^"_A2]\(_#W2;77([*+4I
M+.W>Z6WM&@82^2@82YD??(&#9?(!/85W-`"444N*%J`E%%%`#3&K9XP3WJI(
MC*YSS]*NU#)]YOK0!5Z].M.$18?,.#4H4#H!3AUH`\V\8$_V_<J22%V8!/3Y
M!6+6SXP!'B&[S_L?^@+6-79'8^=Q'\67J%%%%,Q"BBB@`HHHH`****`"BBB@
M`HHHH`****`"BBB@`HHHH`QO%O\`R!)?]]/_`$(5PHZ5W7BW_D"2_P"^G_H0
MKA1TKJI?">1C?XOR_P`SV/\`9]_U&N_[UO\`^U*]:[5Y-^S^I6VUMB"%9X0#
MC@D!^/UKUGM7G5_XC/KLJ_W2'S_,****Q/1"BBB@"Q8_\?<7^]6]6#8_\?<7
M^]6]0!AZG_Q^/]!_*JM6M3_X_'^@_E56@`HHHH`****`"N:^(6AW.O\`A\PZ
M<HDGAF658^A<`$$#WYKI:1G"''4]Q33L[F=6FJD'![,^;IH)+>=H9XWCF4X:
M-E(8'TQ6MI_AV6?Y[L^2G]TCYC_A7L^J:1:ZLX>ZA1I$4A)0,,H]`:Y?4_#5
MQ8C?#F>(=UZK]1_A74JZ:MU/"EE7LGS/5&!;6<-I'LMD6,'J1U/XU/1VS2JI
M=@J`DGH!2UO=EI):(R;[FX;\*9;V\ES)Y<",[GL.WU]*WE\-22W)>_)B3@[`
M/F/^%;-O:Q6D02W144>G]30YHJ&&<G>6@EG";:SAB<@M&N&QZU+1161Z$596
M"BBB@84`X_&BB@"O+9I)EH\(W\ZIRQ/`V)!QZXXK4H8!EPP!![$9JDS&I14M
M49`8'I2U:FL!DFW/_`355_D;:X(;T(IG+*$HO4****"`HHHH&%%%%`!1110`
M4444`9^O?%C2OA=I\?\`:-MJ&I:EJ]PL&FZ9IT/FW%VXZA5XSC*_F.#72_#7
MXBR^/X-0^W^&O$'AF[TV14EAU:W\OS"P)!1OX@`.>.,CK7G?C7P1XEU37/#7
MB_X=Q6=_K'@^ZG)TV[E$2W<5Q&$<*YX5@JD<D?>SG(P?1OAWK?C776U"?X@^
M'=.\-VVZ-=/M8=1%U-C!WF5E^3&=N,$'J".`3K4A#V*DK7]=5KV,,'7Q+QKI
MU&U!/1*%XM<M[N=M'S75KKIIK<R]7^-VC:-\6=.\!SV]T]]?QJ3=KM$,$CJ[
M)$V3G<P08_WAZ&M#XN_%*R^$/A,:]JUG=7UL;N.W,=L5#98$@_,<8^6O!]>^
M!7Q'U^3Q'XRANK>QURX\10ZE8:%)%"\D@MF*VQ^T^9A=L4C_`"]#CZ5ZE^T/
MX/U[XC_#;3;/P_IHEU`ZI:W5Q:2SQCRD56W@LS;3@D#@G-5*CAU.FD].IST\
M?FD\-BG*DU)7=/W>CO96UNU;5/77;8Z/1?BWI?B+QS8>'=&AGN%U/P\NN6]^
MK+Y1A:0QA",[@V1GVJA\1?C79^!==M=`TS1-:\4^(KN`W']FZ3!YCP0Y(\R0
M_P`()'OVSC(SQ/PK^"&L_#?X[:C?6R^=X-31YH-(E,RDVJRSK-]FVYW#:YEP
M<8((.<G`T_&WA#QCX1^+LGCWX<Z3:>)8=6TM=/U'3)+Q;26,JPVR([_+MPB\
M=<YXYR!TL.JMD[JW>UWYOH7]<S26!<YP<9\]G:-VH]TOM:[/71WUL>D>#/&/
M_"8>%H]9?2-6T5B9%DL=3M_*G1D)#9&>F0<'O7$_##X]O\4]0LAIW@[Q-9:7
M>K*4U:YB4VH*9!&\'J64K]:[+P;=>)M7\*-+X]TW3]*U><R[;.RN?.6*,D[%
M9NF\`X."1D9XS@>'_LV?#+Q+\--3L(?$7@.:TN989X;W7?\`A(TE18RQD4"U
M5B,DJBY'/?N:B%.DX5&]UMK_`,'7\2Z^*QL<3A(POR23YGRZ[QM=<KY;ZZ/E
M]3T3XE?'BW^'/BR+04\-:YK]VVE_VE)_9JH_EP!W5B02#@;"2>G-=UX-\66'
MCKPOIVO:$TC6&IPB2+S``Z\D%6`)`(((/)Y'>O%OC/\`!77?B5\4C>Z;/=Z;
MIO\`PB,EG'?V]ZL.;OS9&6*1<[FC8.`P`P0>M>H?![3;_1?AKH.FZ]I$6AW^
MG6JVTUI%,LJY3C>&4D'=][KG).<]:*U.BJ,91^+J:9?B,QEF=:%>+]EKRZ66
MC75+\]^FS+?Q!\977@C1(]0T_P`/ZSXD=[@1/:Z7$'DC4JS&1A_=&T#_`(%7
M,_"7XV-\67#V/A77M+TQ[9YH=4NT4V\S)($,:L.K9+<?[)KT>[C:6TG2,?-)
M&RCG')'_`-:O/?V=O!VK>!/A!HFB>*;;['J-HUQYL/F+)LW3R.OS*2#PP/7O
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M6^IWT:BWGPRJ$5AU)R3_`,!-9?Q`_:+M/`7B_4]#?PQX@U?^Q;.*\O[JP1'2
M"!@#O8$Y`&>2<"N>_9G\!Z]\.I?L6N^")=$DGLMM]K!\1)=I<.C955MU)\O.
MYNAQQ61\8/@)XG^('Q%\9ZII;W=C;76@PIIDL-^D4=]/'LW6\J[@Q5@&`)PN
M<$GC%:JCAO;R3:Y>FOGY,X:N,SC^R:52G%NLWJN76W*W:SC'2Z2O;RNV?0^@
MZY:>)-!L=8TMRUEJ5K'<P/(NT^6ZA@2.QP:XGX1?''1?C#-K4>@VUS:G1YE7
M-PR_Z1&Q8+(F#T^1LCMWJ'6+/Q*_P%ET[P]X>&G^)'T5;"+28;B)%M&($1V/
MOV[53<ZG=G`&>>*X7X:?!CQC\*/B-X>O?MUIK^CSZ*VE:B]O:1V9L4CP\1*^
M83,2Y(W@;L9S6,:5+DFVU?6VO;_,]&KC<?'$X90IMP:7.U'K+1;ZJSU:MHM[
M'9_$KX[P?#SQ8F@1>&]>U^\.E'4Y#ID:OY<`=U8D9S@;,D^];<GQ5L;GX4GQ
M[X?L;W5M-%H;K[-"56;8I(D&"<93#9&?X3BN#^)OP6U/XB_&ZVU!KO6-)\.#
MPP;*?4-)OXX)6F\Z0F`@[CL9'Y^7!XKUSPKX3T[P;X8L=`T.'9IUA`8HD<[B
MP))8MZEB23ZDFE46'C3A;?J:8669UL57532GJHMI7OI9K2[6^][]#D?"GQNT
MKQQXML-$\*V=Y?+<Z-'JEU>J5$5BL@^6*3G/F$XX]_8UZ,>O'2O(_P!G?X93
M_#:P\5Q:CI<.FR7_`(AGDL_+E20O9*%$`RI.`,O@'D;CQS7K=8XA4U.U/8Z\
MGGBYX6-3%?&^EK6\N_GKW"H7^^WUJ:H7^^WUK$]0;2TE%`')^-="DN"+ZT4N
M47;*H&3@="*XG\#7L58>L>$[35-SQ@6UP?XX^C?45M3J=&>=B<$Y-S@><XQ1
M6EJN@WFD,?M49:/M*@RI_'M^-9P&:W33V/*E"479JPE%!&**"0HHHH`****`
M"BBB@`HHHH`****`"C&:,5>L=(GOB"B^7'_?8<'Z4-V*C!MV*./4@'ZT$8-=
MC8Z5!8K\J[Y"/F=N_P#A2W>EV]ZI$B`,>CJ,$5G[17.KZG*V^IYKXMXT67/]
M]/\`T(5Q=C87&I7<5K80R7%Q,VU(XUR6->T7'PWEUP?9KBZ%O;,RL9`F7(!Y
M`!XS[UV_ASPEI?A6W\O1[98V8?O)F^:1S[M_3I6T<1&,+'$\IJUZW-+2/];%
M7P%X7_X1+P[!:2$-<N?-N&7H7('`]@!BNAI:2N&3;=V?34Z<:<%".R"BBBD6
M%%%%`%BQ_P"/N+_>K>K!L?\`C[B_WJWJ`,/4_P#C\?Z#^55:M:G_`,?C_0?R
MJK0`444O\J`$H9@HY/X4QI>H`_&HCR<GDT`/9R3P<"F444`%'7KVHHH`R]1\
M.VNH-OP89/[R=_J*FT[1[;3`#"FZ0=9&.6/^%7J*?.TB%2@G>VI@:IQ>R@>H
M_D*J5;U7_C^E^H_D*J5HC"6X4444""BBB@`HHHH`****`"DDC25<2<^_>EHI
MW$TFK,HRV+)EHLNH[>E5\_7BM8$BHYK>.<?,"&]133.>I1[&;FBGRV[0.`W(
M/1J93.>2LPHHHH$%%%%`!11FBBP'3>#<>5>9_OI_6NCKG/!O^IO/]]/ZUT9Z
MUE4W/6PW\)!DX^M`)!X.*2BH-P[8XI<GVI**`%SD\_K1T&,"DHH`7<:"Q/4D
MTE%`!2YI**`#Z@?E2]1_/WI**`%SQU/YT9)__7244`*"1CMCICM1DXZGFDHH
M`7/K2444`+G-)12T`%5W/SM]:KZMKMEHD>Z^F4-_#$OS.WX?XUS4_B275HR\
M"F"%R1MW98@$CDU:@VKF4Z].#LWJ;E]K,%H2F?,D[A3T^M4U\3#/S0MM]G&?
MY5@YH!Q5\B.66(FWH=E::A!>)F%_F[J>"*L5PZ2-&P:,E6'0@]*V+/Q"R@+>
M@D=G7K^(J7#L;0Q">C-YXTD0I(JLK=01D&N8UCP5%-NETQA"YY\MLE3]/3^5
M=+!/'<1AH'$BGN*EJ5)Q-9TX5%JCR.]LI[";RKN-HW'KW^GK4!&*];O+&#4(
M3%=QI(A[,.GT/45QVL^"I+?=)I3&:,G_`%3??'T]:WA4ON>57P4H*\=4<K13
MI(FB<I*I1UZJPP132,&M#A:L%%%%`@HHHH`***?%$\T@2)2S-T`%#=AI7&XJ
M:ULIKQ]L"%O4]A6Q8>'#Q)?G'I&I_F:W(XTA39$JH@_A48%0YHZZ>$;^(R[#
M0(8,/<_OG[`_='X=ZUJ='$TIP@)J_!IZJ`9AN;L,\"L92OK<]&E225DBI!:O
M<'Y>%'<U?@LTA&2-S>IJP!M&!Q14.3.B,$@QZ_SJ6.X9.#\R^E144BR^D@D^
MZ1GTI:H`D=#CZ5-'<G@.,CUH`LT4`AAE2#]**`"BBB@"Q8_\?<7^]6]6#8_\
M?<7^]6]0!AZG_P`?C_0?RJK5K4_^/Q_H/Y55H`*;*2%&/XJ=3)ONK^-`$5%%
M%`!1110`4444`%%%%`&#JH(O7)_BP1^0JG70WUDMW%\IV2*/E/;\:PY[=[=L
M2*1Z'L?H:TCL<THM,BHHHIDA1110`4444`%%%%`!1110`4444`-F031,OJ.*
MREX'-;"]:QT^Z/I5(Y*\4FA:***I;F`R:9($+RL%11DL2`!7*:SXZCBW1:0J
MROT,K_='T'>H?B"[JUH@=MC%SM[9&T5QW2NFG25KGGXC$SC)QB='IOC>\MY?
M^)A_I,1.3D`,OTQ7::;K-KJL>^SD#$#YE)PR_A7E%:_A[2[BXU"UD0F&/S5_
M>=\9Z"B=-:F>'Q%1.VY[OX.B86MQ(1A9'&W\.O\`.N@-16UO':P)%`H5$&`!
M4E>?)W9]=3AR040HHHJ2PHHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`*4
M]*1B%&7(4`9))KD];\?VUGNBTD+<S=/,S\B_X_YYJE%O8RJUHTHWDSI[N\@L
M(&FO94AC7J6.*XC6_B!+*Q@T)"`>/.<98_1>U<KJ.I7.JW!FOI6D<]!T`]@.
M@K7\'(IFN6*C>H7:WIG.:W4%"-V>;+&3K5%"&B_$;9^&[B_D\_5WD0.<X9LN
MWU]*Z--'@%LB6X,6T8'.?SJ7-68ON`5+DV=5*A3@N]_O,.XM)+8_O%^7LPZ&
MH:Z1U#(P.""*YS&,^QH1G5I\K$H!Q113,R6WNY;5]T#E3W]#]:WK#Q!'*`EW
MB)^@/8USE`XJ7%,N%64-CNE(=05((/0@TM<?9:E-9']TP*=T8<&N@T_5X+T!
M0?+D/\#\?D>]9N+1VPK1EOH-U70K35T/VF/$F.)$&&'^-<3J_A2[TS=)&#<6
MX_C1>0/<5Z1T-)BG&;3,ZV%IU-]SQ['I2$8KT36/"-KJ6Z2#;;3DYW*ORL?<
M#^8KBM3T2ZTB0+=Q_(?NR+]TUO&I%GDUL+4IO78H44459S`.M=%X9A3R9I<#
M>6VY]L9_K7.CK78^&-,F6T)G1HED?<N\8)&!SBHJ-)'7A(-U$70"S849/H*M
MPV!)!F./]FKL5ND(&Q0#W..34E<[EV/8A3MN-1%1<*`!3J**DU"BBB@`HHHH
M`****`)K8D2X[$5:JI;_`.M'T-6Z`"BBB@"Q8_\`'W%_O5O5@V/_`!]Q?[U;
MU`%&[@C,N60$D<G)J'[/%_SS'YG_`!HHI`'V>+_GF/S/^-(;6%NL8X_VC_C1
M10`GV.#_`)YC_OH_XT?8X/\`GF/^^C_C110`?8X/^>8_[Z/^-'V.#_GF/^^C
M_C110`?8X/\`GF/^^C_C1]C@_P">8_[Z/^-%%`!]C@_YYC_OH_XT?8X/^>8_
M[Z/^-%%`!]C@_P">0_[Z/^-,DTZVE4K)"K`]BQ_QHHHNP:ON5_\`A'M._P"?
M4?\`?Q_\:/\`A'M._P"?4?\`?Q_\:**+L7*NP?\`"/:=_P`^H_[^/_C1_P`(
M]IW_`#ZC_OX_^-%%%V+E78/^$>T[_GU'_?Q_\:/^$>T[_GU'_?Q_\:**+L.5
M=@_X1[3O^?4?]_'_`,:='X=TUG`-J,'_`*:/_C11338<J[%G_A%=+_Y]?_(K
M_P"-'_"*Z7_SZ_\`D5_\:**=V'*NP?\`"*Z7_P`^O_D5_P#&C_A%=+_Y]?\`
MR*_^-%%%V'*NP?\`"*Z7_P`^O_D5_P#&H1X)T4=+/_R-)_\`%444KL3IP>Z#
M_A"M&_Y\_P#R,_\`\51_PA6C?\^?_D:3_P"*HHH4GW%[&G_*ON*.H_##PSJQ
M0ZAIOFF/.W_295QGKT8>E4_^%,>#O^@/_P"3D_\`\7115>TFMF2\-1;NX+[D
M/C^#OA")U=-'&5Z9NYB/R+U>C^'/AV)U:/3\,A!4_:)>,?\``J**/:3?4%AJ
M*V@ON1N?V=;_`///_P`>/^-']G6__//_`,>/^-%%2;!_9UO_`,\__'C_`(T?
MV=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_
M`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>
M/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?
MV=;_`///_P`>/^-%%`!_9UO_`,\__'C_`(T?V=;_`///_P`>/^-%%`!_9UO_
M`,\__'C_`(T?V=;_`///_P`>/^-%%`%/4?#&G:M$([^!Y(QSL$[J#]0&&?QK
M._X5MX<_Z!W_`),R_P#Q5%%--K8SE2IRWB@_X5MX<_Z!W_DS+_\`%58L_`^B
M:>6-I9>67QN_?R'./JU%%/FEW!4::=U%?<6O^$9TW_GV_P#(K_XTJ^'-.3.V
MWQG_`*:-_C112NR^5=AW_"/Z>1_Q[_\`D1O\:K?\(;H__/H?^_TG_P`5111=
MB<4]T)_PAFC_`//H?^_S_P#Q5'_"&:/_`,^A_P"_S_\`Q5%%',^Y/)'L'_"&
M:/\`\^A_[_/_`/%4?\(9H_\`SZ'_`+_/_P#%444<S[AR1[!_PANC_P#/H?\`
MO\__`,52CP=I`.1:$$?]-Y/_`(JBBB[*4(]B['HUG$@1(CM7IF1C_,T[^RK7
M_GE_X^W^-%%(H/[*M?\`GE_X^?\`&F2Z+931LDL"NC#!!)(/ZT44`9)^'?AX
MG/\`9_Y7$O\`\51_PKKP]_T#S_X$R_\`Q5%%5S2[F7L*7\J^XEM?`>A6<PE@
ML%$B]"TKMC\V-:7]C6?_`#Q_\?;_`!HHI-M[E1IPCLK!_8UG_P`\?_'V_P`:
M/[&L_P#GC_X^W^-%%(L/[&L_^>/_`(^W^-']C6?_`#Q_\?;_`!HHH`/[&L_^
M>/\`X^W^-']C6?\`SQ_\?;_&BB@`_L:S_P">/_C[?XT?V-9_\\?_`!]O\:**
M`#^QK/\`YX_^/M_C1_8UG_SQ_P#'V_QHHH`5=)M$.5BP?]]O\:?_`&=;_P#/
M/_QX_P"-%%`!_9UO_P`\_P#QX_XT?V=;_P#//_QX_P"-%%`"QV$$3AT3##H=
(QJQ110!__]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g884256002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g884256002.jpg
M_]C_X``02D9)1@`!`0$!+`$L``#_X@Q824-#7U!23T9)3$4``0$```Q(3&EN
M;P(0``!M;G1R4D="(%A96B`'S@`"``D`!@`Q``!A8W-P35-&5`````!)14,@
M<U)'0@``````````````````]M8``0````#3+4A0("``````````````````
M`````````````````````````````````````````````!%C<')T```!4```
M`#-D97-C```!A````&QW='!T```!\````!1B:W!T```"!````!1R6%E:```"
M&````!1G6%E:```"+````!1B6%E:```"0````!1D;6YD```"5````'!D;61D
M```"Q````(AV=65D```#3````(9V:65W```#U````"1L=6UI```#^````!1M
M96%S```$#````"1T96-H```$,`````QR5%)#```$/```"`QG5%)#```$/```
M"`QB5%)#```$/```"`QT97AT`````$-O<'ER:6=H="`H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0``9&5S8P`````````2<U)'0B!)14,V,3DV
M-BTR+C$``````````````!)S4D="($E%0S8Q.38V+3(N,0``````````````
M````````````````````````````````````````````````````6%E:(```
M`````/-1``$````!%LQ865H@`````````````````````%A96B````````!O
MH@``./4```.06%E:(````````&*9``"WA0``&-I865H@````````)*````^$
M``"VSV1E<V,`````````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````
M````%DE%0R!H='1P.B\O=W=W+FEE8RYC:```````````````````````````
M``````````````````````````````````!D97-C`````````"Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M('-21T(`````````
M`````"Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92`M
M('-21T(`````````````````````````````9&5S8P`````````L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0``````````
M````+%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$``````````````````````````````````'9I97<``````!.D_@`47RX`
M$,\4``/MS``$$PL``UR>`````5A96B```````$P)5@!0````5Q_G;65A<P``
M```````!`````````````````````````H\````"<VEG(`````!#4E0@8W5R
M=@````````0`````!0`*``\`%``9`!X`(P`H`"T`,@`W`#L`0`!%`$H`3P!4
M`%D`7@!C`&@`;0!R`'<`?`"!`(8`BP"0`)4`F@"?`*0`J0"N`+(`MP"\`,$`
MQ@#+`-``U0#;`.``Y0#K`/``]@#[`0$!!P$-`1,!&0$?`24!*P$R`3@!/@%%
M`4P!4@%9`6`!9P%N`74!?`&#`8L!D@&:`:$!J0&Q`;D!P0')`=$!V0'A`>D!
M\@'Z`@,"#`(4`AT")@(O`C@"00)+`E0"70)G`G$">@*$`HX"F`*B`JP"M@+!
M`LL"U0+@`NL"]0,``PL#%@,A`RT#.`-#`T\#6@-F`W(#?@.*`Y8#H@.N`[H#
MQP/3`^`#[`/Y!`8$$P0@!"T$.P1(!%4$8P1Q!'X$C`2:!*@$M@3$!-,$X03P
M!/X%#04<!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&
M609J!GL&C`:=!J\&P`;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E
M!_@("P@?"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)
MN@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X`+F`NP
M"\@+X0OY#!(,*@Q##%P,=0R.#*<,P`S9#/,-#0TF#4`-6@UT#8X-J0W##=X-
M^`X3#BX.20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[!`)$"800Q!A
M$'X0FQ"Y$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3
M(Q-#$V,3@Q.D$\43Y10&%"<4211J%(L4K13.%/`5$A4T%585>!6;%;T5X!8#
M%B86219L%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$`891B*&*\8U1CZ&2`9
M11EK&9$9MQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H<`APJ'%(<>QRC
M',P<]1T>'4<=<!V9'<,=[!X6'D`>:AZ4'KX>Z1\3'SX?:1^4'[\?ZB`5($$@
M;""8(,0@\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_`D'R1-
M)'PDJR3:)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$H
MHBC4*08I."EK*9TIT"H"*C4J:"J;*L\K`BLV*VDKG2O1+`4L.2QN+*(LURT,
M+4$M=BVK+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C`U,&PPI##;,1(Q2C&",;HQ
M\C(J,F,RFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I
M-R0W8#><-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\
M93RD/.,](CUA/:$]X#X@/F`^H#[@/R$_83^B/^)`(T!D0*9`YT$I06I!K$'N
M0C!"<D*U0O=#.D-]0\!$`T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(
M!4A+2)%(UTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I-`DU*39--W$XE
M3FY.MT\`3TE/DT_=4"=0<5"[40914%&;4>92,5)\4L=3$U-?4ZI3]E1"5(]4
MVU4H5755PE8/5EQ6J5;W5T17DE?@6"]8?5C+61I9:5FX6@=:5EJF6O5;15N5
M6^5<-5R&7-9=)UUX7<E>&EYL7KU?#U]A7[-@!6!78*I@_&%/8:)A]6))8IQB
M\&-#8Y=CZV1`9)1DZ64]99)EYV8]9I)FZ&<]9Y-GZ6@_:)9H[&E#:9II\6I(
M:I]J]VM/:Z=K_VQ7;*]M"&U@;;EN$FYK;L1O'F]X;]%P*W"&<.!Q.G&5<?!R
M2W*F<P%S77.X=!1T<'3,=2AUA77A=CYVFW;X=U9WLW@1>&YXS'DJ>8EYYWI&
M>J5[!'MC>\)\(7R!?.%]07VA?@%^8G["?R-_A'_E@$>`J($*@6N!S8(P@I*"
M](-7@[J$'82`A..%1X6KA@Z&<H;7ASN'GX@$B&F(SHDSB9F)_HIDBLJ+,(N6
MB_R,8XS*C3&-F(W_CF:.SH\VCYZ0!I!ND-:1/Y&HDA&2>I+CDTV3MI0@E(J4
M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY`
MGJZ?'9^+G_J@::#8H4>AMJ(FHI:C!J-VH^:D5J3'I3BEJ:8:IHNF_:=NI^"H
M4JC$J3>IJ:H<JH^K`JMUJ^FL7*S0K42MN*XMKJ&O%J^+L`"P=;#JL6"QUK)+
MLL*S.+.NM"6TG+43M8JV`;9YMO"W:+?@N%FXT;E*N<*Z.[JUNRZ[I[PAO)N]
M%;V/O@J^A+[_OWJ_]<!PP.S!9\'CPE_"V\-8P]3$4<3.Q4O%R,9&QL/'0<>_
MR#W(O,DZR;G*.,JWRS;+MLPUS+7--<VUSC;.ML\WS[C0.="ZT3S1OM(_TL'3
M1-/&U$G4R]5.U='65=;8UUS7X-ADV.C9;-GQVG;:^]N`W`7<BMT0W9;>'-ZB
MWRG?K^`VX+WA1.',XE/BV^-CX^OD<^3\Y83F#>:6YQ_GJ>@RZ+SI1NG0ZEOJ
MY>MPZ_OLANT1[9SN*.ZT[T#OS/!8\.7Q<O'_\HSS&?.G]#3TPO50]=[V;?;[
M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____VP!#``,"`@,"`@,#
M`@,#`P,#!`<%!`0$!`D&!P4'"@D+"PH)"@H,#1$.#`P0#`H*#A0/$!$2$Q,3
M"PX4%A02%A$2$Q+_VP!#`0,#`P0$!`@%!0@2#`H,$A(2$A(2$A(2$A(2$A(2
M$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A(2$A+_P``1"``S`LL#
M`2(``A$!`Q$!_\0`'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`
MM1```@$#`P($`P4%!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*Q
MP152T?`D,V)R@@D*%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA9
M6F-D969G:&EJ<W1U=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*S
MM+6VM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ
M_\0`'P$``P$!`0$!`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#
M!`<%!`0``0)W``$"`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1
M"A8D-.$E\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI
M:G-T=79W>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1
M`Q$`/P#]0;K4I8+AT18R%Z9!_P`:A_M>;^[%^1_QJ+4/^/R7ZC^55J`+W]KS
M?W8OR/\`C1_:\W]V+\C_`(U1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO
M-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_
M=B_(_P"-']KS?W8OR/\`C5&EH`N_VO-_=B_(_P"-']KS?W8OR/\`C7+ZEXGB
ML9VAAB:=T.'.=H!]/>LN7Q9>/D1I!&#T^4DC]:KD9A+$TXZ7.\_M>;^[%^1_
MQH;6944LPA`'<@_XUYO-KE_.H#W,@Q_<PG\L52E=IF+2LSL1]YCD_G5>S,98
MU=$=Y/X]CMQEY[$C.,)EB/P!JE+\4(X_N(LOH4C.#^;"O.71D/S@BFTU!&,L
M9-[([N;XK71!%O96X/8NQ/Z`_P!:K_\`"U-5_P"?;3_^_;__`!5<913Y49O$
M57U.S_X6IJO_`#[Z?_W[?_XJC_A:FJ_\^^G_`/?M_P#XJN,HI\J%[>IW.S_X
M6IJO_/OI_P#W[?\`^*H_X6IJO_/OI_\`W[?_`.*KC**.5![>IW.S_P"%J:K_
M`,^^G_\`?M__`(JC_A:FJ_\`/OI__?M__BJXRBCE0>WJ=SL_^%J:K_S[Z?\`
M]^W_`/BJ='\5=3##S;6Q9>X57!_/<:XJBCE0>WJ=ST"'XK2-_P`?%FB?[F6_
MF15V+XE02XR\,9/9XG'ZYKS*BDX(T6+J+?4]:B\9F=ML$EC(?16R?YU/_P`)
M+<_W+?\`[Y/^->/5-#>7%NN()Y8QZ*Y`J?9FL<;W1ZW_`,)+=?\`/.#_`+Y/
M^-'_``DMU_SS@_[Y/^->9P^)M0A(S,L@`Z/&#_+FKD/C*8$_:;:-_0QL5_QI
M<C-HXNFST#_A);K_`)YP?]\G_&C_`(26Z_YYP?\`?)_QKGM-U.'5(2]ON&T@
M,K#!!JW4/0Z(R4E=&M_PDMU_SS@_[Y/^-'_"2W7_`#S@_P"^3_C6310,UO\`
MA);K_GG!_P!\G_&I[77KB?=O2$;1V!_QK"J[8HR!RPQD<4`:W]KS?W8OR/\`
MC1_:\W]V+\C_`(U1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_=B_(_X
MT?VO-_=B_(_XU1HH`O?VO-_=B_(_XT?VO-_=B_(_XU1HH`O?VO-_=B_(_P"-
M']KS?W8OR/\`C5&B@"]_:\W]V+\C_C1_:\W]V+\C_C5&B@"ZVM2H,LL>/8'_
M`!J,^().R1G\#_C5*X_U?XU6H`TSX@N.R0C\#_C1_P`)!<?W(?\`OD_XUF44
M`:?_``D%Q_<A_P"^3_C1_P`)!<?W(?\`OD_XUF4$XH`T_P#A(+C^Y#_WR?\`
M&C_A(+C^Y#_WR?\`&LK=1N-`%'5_B'J-AJ,D$,%DR(%P61B>0#_>JH/B;JS'
M"6UBQ]!$Y_\`9J@U2)'OY&=$+<<E1Z5"`!TK6R['`_:<S]XN3>/O$TO-G!I4
M8QTFM9#_`.U151_'?C=&)$/AAHQZ13[ORWX_6DI#T/T_K3NNQ,HR?VG]Y'!\
M6-?4YN8]'<>B6TBX_$RFIO\`A;6L?\^VF_\`?M__`(NN)_A%%:\D>QP/$UD[
M<S.V_P"%M:Q_S[:;_P!^W_\`BZ/^%M:Q_P`^VF_]^W_^+KB:*.2/87UJM_,=
MM_PMK6/^?;3?^_;_`/Q='_"VM8_Y]M-_[]O_`/%UQ-%')'L'UJM_,=M_PMK6
M/^?;3?\`OV__`,71_P`+:UC_`)]M-_[]O_\`%UQ-%')'L'UJM_,=M_PMK6/^
M?;3?^_;_`/Q=0S_%C7F(^S1:0@QSOMI&_E(*X^BCDCV#ZS6_F.BF^+?C!#^X
MMO#DB^\,RG_T9_6J,_QL\;6XR^CZ,1G'R0R/_*6LNBJ2CV,G5KO:HT32_M#^
M*H'VSZ;HT;?W7MYE/ZR5'_PT?XE_Y\=#_P"_,O\`\<IO48/0]:IS:/8S@B6T
M@Y.253:?S%4E3ZQ,7/&=*K+W_#1_B7_GQT/_`+\R_P#QRN@T3XJ>/=>MH[FR
MTG0!:RYVS2*X!P<'CS<]0>W:N#F\(Z?*1L$T/^X^?YYKT?P78)8>&[6UADWK
M&7))ZC+DX/YTJGLTKQ1O@EBZE6U6H[>3-FS\5^,''^GOX:A.>D-K/+_.1:U[
M?Q;J*Q*+H64DO=HX60'\"Y_G62R%>OYTVN9V9[\(<O5OU.A@\4W<N[=';C`[
M*?\`&K(\17&>8X2/H?\`&N>L_P"/Z5<K-[FJ-<>(I?XHX_P!_P`:D37G<X"I
MGW4_XUB5)!_K5^M(9M?VO-_=B_(_XT?VO-_=B_(_XU1HH`T8=5EDF1&6/#,`
M<`^OUK4KG[7_`(^8?^NB_P`ZZ`=*`,/4/^/R7ZC^55JLZA_Q^2_4?RJM0`44
M44`%%%%`!3)YXK:,R7,L<4:]7=@H'U)I]<%\8<?V/8_]?)_]!-5&/,TC'$U?
M94G4['0WGCC0;''G:I;-G_GB3+_Z`#6+=_%K2(=PM8KRX8?=(0*I_$G(_*O(
M*/Z5U*A%'S\\YKOX4D>C7'QCE8$6FEQH>QDG+?H`/YU8MOC)&7`O-+=%[M%/
MN/Y$#^=>:102S_ZB.23_`'%)JY'H5[*JD0E0W]X@8_#K3=*'8RCF&->S_!?Y
M'07OQ*T2XU.Y,KW-MF1C^]A)_P#0<U;M?$VDWH3[-J%HQ?A5,H5C_P`!/->>
M77@BYGOIGGGAB5G)&T%C^7%3VW@6V3_CXN9I,'^`!!_6K<*=MR(XC%-MN*_(
M]/!!Z'-%3:3IMO;:3911HQ6*!%7+'H%%6_LL7]S]37.VCUHT)-)F:5!Z@4QK
M>-NJ+^`Q6D;*,]"P_&HS8'^%Q^(I70.C-&:UC&>A(J(Z>>S@_A6H;.4=`&^A
M_P`:C,3KG<C#'M3,W%K=&8;*4=@?H:B:&1>J-Q[5J@@G@YHQ0(Q\T5KE%;[R
M@_45&UK$W\(!]J`,RBK[6"'[K$5$U@X/RL#^E`%6BIC:2C^'/T--\B3_`)YO
M_P!\F@".BI!;RGI&WXC%2+92'J`OU-`%>BKBZ?\`WG_(5(+&,=<GZT`9]*%)
MZ`GZ"M18(T'RHOY4\#'2@#6\&6TK6]R0A`\Q>3QV/^-=*MDY^\5'ZUF^#O\`
MCVN_^NB_RKH#UK&:LSU\-_"15%BO\3D_08J06L0_A)^IJ6BI-A%14^XJK]!2
MT44`%%%%`!1110`4444`%%%%`!1110`4444`-E4NF%ZU6:-EZJ?PYJW2T`4<
M45=(!ZC--,2-U44`5*1_O&K1MU[9%0/"0YYH`BHI_E-[4OD\<F@#G]2_X_9/
MP_E5:J'BG4[BUU>>&`JBJ%(;;DGY16%)J5S)]^:3GKAL#\A70H71Y57$QC-H
MZJ21(EW2,J+ZL<"JL^JVL(.Z96..`GS9_*N6)W')Y-%5[,PEBV]D'844459R
M-W84444""BBB@`HHHH`****`"BBB@`HHHH`*56*'*D@CH0:2B@+B:MXBU+3M
M+N)K2\F61%&TN=^.1V;(KG[/XL:Y;*!/]CN^>6EAP?\`QT@?I5_Q'_R!+K_=
M'_H0KSZMZ<(R6J.'%8JO2J+DFT>]_#GQB?&<][&UJ+0VRIR)=^[<3VP,=*[X
M6J+][+?C7CWP"4_;-7;!VA8<G'NU>S&N"O%1J-(^FRRM.KAHSF[O7\Q@AC'1
M!^/-.`QTHHK(]`****`);7_CYA_ZZ+_.N@'2N?M?^/F'_KHO\ZZ`=*`,/4/^
M/R7ZC^55JN7T$KW<A2.1@2,$*?2H/LLW_/&7_O@T`145+]EF_P">4O\`WP:;
M);3\;89>G.$-`##QUI"ZCO2?8[C_`)X3?]\&C['/_P`\)O\`O@T`'FCWJEJ6
MGVFKPB+4K:*XC4Y`D&=I]0>H/TJ[]CG_`.>$W_?!H^QS_P#/";_O@T)V%)*2
ML]CDIOAMH,AREK)%_N3N?YDU%_PKNSB(^RNB;?NEH0S#\<UV7V.?_GA-_P!\
M&C['/_SPF_[X-7[27<Y_JE#^1'$2>$+Q/]6T#@>C$?TJ2'P=<N?W\T,8_P!G
M+'^E=G]CG_YX3?\`?!H%G/\`\\)O^^#1[20+"4TSSNX\*0QW,HGFED(;'R@+
M_C4D>@V,>,0[B.[,3FNLOO#UU+*TD,<AW')4QD52?0=03K:3D>R$U?.V9?5X
M1?PF>`%4!0%4#``&`*6K?]CW_P#SY7?_`'Y;_"C^Q[__`)\KO_ORW^%*Z+L5
M**M_V/?_`//E=_\`?EO\*/['O_\`GRN_^_+?X470[,J45;_L>_\`^?*[_P"_
M+?X4?V/?_P#/E=_]^6_PHNA6*;*'^^`WU&:C:UB/\`!]N*T/['O_`/GRN_\`
MORW^%']CW_\`SY7?_?EO\*+B<$]T9;6*'[K,OUYJ-K%A]UE/UXK8_L>__P"?
M*[_[\M_A1_8]_P#\^5W_`-^6_P`*?,0Z$7T,1K65?X<_0U$59?O*R_48KH/[
M(O\`_GRN_P#ORW^%']D7_P#SY7?_`'Y;_"CF,WAET.>HZ=*W9-!NY`=UA=9P
M<$0,#_*L\:'J6/\`D'WW_@.W^%.Z,9TI1=BE15[^P]2_Z!]]_P"`[?X4?V'J
M7_0/OO\`P';_``IJQ'++L4:*K:Y%KNFR(ECX?U.\WJ262VD(4^^%KGKB3QK,
M"(M`U.#T*:9+D?F#6BIM]3&=51=K/[CJJ*Y&"/QPK_-H^K29Z!],<#]%%;VE
MVWBJXFCCO_#US$'<*9/*D4*">O1J3A;J*%7F^R_N.Y\'?\>UW_UT7^5=`>M5
M-&T"72H'0K+(TK!F/ED`<=*O_99O^>4O_?!KFF[L]ZC%QII,BHJ7[+-_SQE_
M[X-'V6;_`)XR_P#?!J34BHJ7[+-_SQE_[X-'V6;_`)XR_P#?!H`BHJ7[+-_S
MQE_[X-'V6;_GC+_WP:`(J*E^RS?\\9?^^#1]EF_YXR_]\&@"*BI?LLW_`#QE
M_P"^#1]EF_YXR_\`?!H`BHJ7[+-_SQE_[X-'V6;_`)XR_P#?!H`BHJ7[+-_S
MQE_[X-'V6;_GC+_WP:`(J*E^RS?\\9?^^#1]EF_YXR_]\&@"*BBX#VR;Y8;D
MC_IG;O(?R4$UF7.MO"<0Z5K=QQG,=@X'_CP%-)LB52,=V:=%<S-XEUGYA;^&
MM1]B\4A_0+_6J]K=^*=49Q);3Z<$P05TYCN_[ZS5>S=KLQ^M0YK)-_+_`#.N
MJM/,D))F=4'JQQ6!)H6J3DM=2:U+N'S*"R(?P4"I+?PNT<>V.QNT&23E7//X
MT<J[E*I-_9-"36+.(X:=3_N@M_*HQKUD?^6C#_@!_P`*IOX6N#DQPW0]C$36
M<=#U')_T"]X/_/!O\*?+%D2JU(O5&U=-I6K)MNS;R@="_P`I'T/!_*J,W@K2
M[CYH#+"O_3.7(/YYJG_8FI?\^%[_`-^&_P`*5=&U-&#)8WRD=Q`P_I5;;,RE
M.,OBA<BF^'_RDVUYD]@\7]<_TK-N/!&I0#*+#/[1R8_GBNACAUR(Y2WU$_[T
M+-_,59BFUM,!]/N9/=K9A_*FI21#HT)?9:.$GT/4+<D2V=QP.2L98#\1Q5(J
M0<8->IQWE_N_>Z3?J.^V)C_2I6C^VIMN]-NRHZ++9LP_D::J/JC-X&#^&1Y-
M17J<O@ZRNQN;370GILC>/'X#%9T_PUA=2;?[;$W;*;A^6,_K356)G++ZJVU/
M/:*[&?X9WRX^S2>9SSYD+)C\LUG7'@/7(2=EA)*J_P`2$<_@>?TJE.+ZF$L-
M6CO$Y^BM+_A&=7'_`#"]1_\``5_\*/\`A&M7_P"@7J/_`("O_A3NC/V<^QFT
M5IIX7UB1PJZ7J&2>]LZC\R,5OZ-X(OD$C:CISALC9O7<,?09I.22+IX><Y6L
M<<%)Z#)]*L1Z9=2D!+>7GH2N!^9KT:#PQ-$N%A>,'JJ0$5870)!U@N6^J&H=
M5';'+WU9YY%X<NY!E_+C_P!YO\,U;B\*EB-\_/=53_Z]=ZNCNO2TE_&,FI!8
M7"C"VTP'H(S4.JS>.!IK<XZ#PG`#S%-)Q_&VW_"ISX-MY!C9Y6>XD)/ZYKJ_
ML-S_`,^\_P#W[-'V&Y_Y]Y_^_9J?:2-OJM+L<5=_#FTOH7@N;JY$$@PPCVAN
MN>"01V]*73_A)X5M$Q<6MU=MG.Z>X;_V3:/TKM/L-S_S[S_]^S1]AN?^?>?_
M`+]FFJLUU(^HX:]W!-^>HFG6=EI=LMOID-O:PKR$B0(,^N/7CK5H$-]TY^E5
MOL-S_P`^\_\`W[-'V*Y'2WG_`._9K,ZDDE9%FBF0VUT'&Z*?!ZY0U8^RS?\`
M/&7_`+X-`R*BI?LLW_/&7_O@T?99O^>,O_?!H`+7_CYA_P"NB_SKH!TK#MK>
M5;B(M%(`'&24/K6X*`%HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****
M`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`
M****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`H
MHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BB
0B@`HHHH`****`"BBB@#_V3\_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g884256003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g884256003.jpg
M_]C_X03Q17AI9@``34T`*@````@`!P$2``,````!``$```$:``4````!````
M8@$;``4````!````:@$H``,````!``(```$Q``(````>````<@$R``(````4
M````D(=I``0````!````I````-``"OR````G$``*_(```"<0061O8F4@4&AO
M=&]S:&]P($-3-B`H5VEN9&]W<RD`,C`Q-3HP,SHP-"`Q-#HQ,CHR,0```Z`!
M``,````!``$``*`"``0````!```"RZ`#``0````!````0@`````````&`0,`
M`P````$`!@```1H`!0````$```$>`1L`!0````$```$F`2@``P````$``@``
M`@$`!`````$```$N`@(`!`````$```.[`````````$@````!````2`````'_
MV/_M``Q!9&]B95]#30`!_^X`#D%D;V)E`&2``````?_;`(0`#`@("`D(#`D)
M#!$+"@L1%0\,#`\5&!,3%1,3&!$,#`P,#`P1#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`$-"PL-#@T0#@X0%`X.#A04#@X.#A01#`P,#`P1$0P,#`P,
M#!$,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,_\``$0@`#P"@`P$B``(1
M`0,1`?_=``0`"O_$`3\```$%`0$!`0$!``````````,``0($!08'"`D*"P$`
M`04!`0$!`0$``````````0`"`P0%!@<("0H+$``!!`$#`@0"!0<&"`4###,!
M``(1`P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U
M%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1``("`0($!`,$!08'!P8%-0$``A$#
M(3$2!$%187$B$P4R@9$4H;%"(\%2T?`S)&+A<H*20U,58W,T\24&%J*R@P<F
M-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:F
MML;6YO8G-T=79W>'EZ>WQ__:``P#`0`"$0,1`#\`]-L)WG7_`%A1+MH+G.AH
M$DDP``I6#WG_`%[(=H:ZI[;!^C+2'R8]I'N]R2D#^J83)_33`)D!Q;I_+`0?
MMUE]>ZJT;#^<SC_.4/LG36S%K>#HY[3^+BBU,:U@%<%GB'-(_*G:,?KZT/[J
M`FXF2]Q\]Q_O4=]G[SOO*LEK3S'WC^]1-;?$#XEO]Z5HX2A;;:W5MCA_:*-5
ME7E[6D[@2!/!U^"AL`/YOQW-_P#))4.<^YC=CF^X>YVT#0_UTD`D$;M_:_Q(
M^:))\2E!_P!82@_ZD)K,J3XE*3XE*#_J0E!_U(24PEW<E"N)-<$GD<$A%-AF
M&L<X_(#_`#G%`O.YA;;6/3)&N\#7MJB@D4U+W`$;':Z[B"?QU0][_P!]W^<?
M[T8X]#OH6[/)Y:1_G,<AOH>W\YCAXM>W^):C882);U]C`N<1!<XCP)/]Z&:6
MD@[K!!!(:]T'RC<C,J<\P2UH\2YO_DD=N+1^?:#\'-'\4;I7`9=/M9XV739>
M<:K<QX:7;"($:<.!\U=&X#4D_-4\;'PJ\HV5.#\@MB-X)#=)BL*[!_UA--=&
M6/%7JK?IV?_9_^T-'E!H;W1O<VAO<"`S+C``.$))300E```````0````````
M`````````````#A"24T$.@`````!%P```!`````!```````+<')I;G1/=71P
M=70````%`````%!S=%-B;V]L`0````!);G1E96YU;0````!);G1E`````$-L
M<FT````/<')I;G13:7AT965N0FET8F]O;``````+<')I;G1E<DYA;65415A4
M````&@!<`%P`4P!.`$<`1@!"`%4`+0!-`%<`4P`M`$8`4``Q`#``7`!B`',`
M:0!?`'``<@`S```````/<')I;G10<F]O9E-E='5P3V)J8P````P`4`!R`&\`
M;P!F`"``4P!E`'0`=0!P```````*<')O;V93971U<`````$`````0FQT;F5N
M=6T````,8G5I;'1I;E!R;V]F````"7!R;V]F0TU92P`X0DE-!#L``````BT`
M```0`````0``````$G!R:6YT3W5T<'5T3W!T:6]N<P```!<`````0W!T;F)O
M;VP``````$-L8G)B;V]L``````!29W--8F]O;```````0W)N0V)O;VP`````
M`$-N=$-B;V]L``````!,8FQS8F]O;```````3F=T=F)O;VP``````$5M;$1B
M;V]L``````!);G1R8F]O;```````0F-K9T]B:F,````!````````4D="0P``
M``,`````4F0@(&1O=6)`;^````````````!'<FX@9&]U8D!OX```````````
M`$)L("!D;W5B0&_@````````````0G)D5%5N=$8C4FQT````````````````
M0FQD(%5N=$8C4FQT````````````````4G-L=%5N=$8C4'AL0%(`````````
M```*=F5C=&]R1&%T86)O;VP!`````%!G4'-E;G5M`````%!G4',`````4&=0
M0P````!,969T56YT1B-2;'0```````````````!4;W`@56YT1B-2;'0`````
M``````````!38VP@56YT1B-0<F-`60```````````!!C<F]P5VAE;E!R:6YT
M:6YG8F]O;``````.8W)O<%)E8W1";W1T;VUL;VYG``````````QC<F]P4F5C
M=$QE9G1L;VYG``````````UC<F]P4F5C=%)I9VAT;&]N9P`````````+8W)O
M<%)E8W14;W!L;VYG```````X0DE-`^T``````!``2`````$``@!(`````0`"
M.$))300F```````.`````````````#^````X0DE-!`T```````0```!X.$))
M3009```````$````'CA"24T#\P``````"0```````````0`X0DE-)Q``````
M``H``0`````````".$))30/U``````!(`"]F9@`!`&QF9@`&```````!`"]F
M9@`!`*&9F@`&```````!`#(````!`%H````&```````!`#4````!`"T````&
M```````!.$))30/X``````!P``#_____________________________`^@`
M````_____________________________P/H`````/__________________
M__________\#Z`````#_____________________________`^@``#A"24T$
M`````````@`!.$))300"```````$`````#A"24T$,````````@$!.$))300M
M```````&``$````".$))300(```````0`````0```D````)``````#A"24T$
M'@``````!``````X0DE-!!H``````TD````&``````````````!"```"RP``
M``H`50!N`'0`:0!T`&P`90!D`"T`,0````$`````````````````````````
M`0`````````````"RP```$(``````````````````````0``````````````
M```````````0`````0```````&YU;&P````"````!F)O=6YD<T]B:F,````!
M````````4F-T,0````0`````5&]P(&QO;F<``````````$QE9G1L;VYG````
M``````!"=&]M;&]N9P```$(`````4F=H=&QO;F<```++````!G-L:6-E<U9L
M3',````!3V)J8P````$```````5S;&EC90```!(````'<VQI8V5)1&QO;F<`
M````````!V=R;W5P241L;VYG``````````9O<FEG:6YE;G5M````#$53;&EC
M94]R:6=I;@````UA=71O1V5N97)A=&5D`````%1Y<&5E;G5M````"D53;&EC
M951Y<&4`````26UG(`````9B;W5N9'-/8FIC`````0```````%)C=#$````$
M`````%1O<"!L;VYG``````````!,969T;&]N9P``````````0G1O;6QO;F<`
M``!"`````%)G:'1L;VYG```"RP````-U<FQ415A4`````0```````&YU;&Q4
M15A4`````0```````$US9V5415A4`````0``````!F%L=%1A9U1%6%0````!
M```````.8V5L;%1E>'1)<TA434QB;V]L`0````AC96QL5&5X=%1%6%0````!
M```````):&]R>D%L:6=N96YU;0````]%4VQI8V5(;W)Z06QI9VX````'9&5F
M875L=`````EV97)T06QI9VYE;G5M````#T53;&EC959E<G1!;&EG;@````=D
M969A=6QT````"V)G0V]L;W)4>7!E96YU;0```!%%4VQI8V5"1T-O;&]R5'EP
M90````!.;VYE````"71O<$]U='-E=&QO;F<`````````"FQE9G1/=71S971L
M;VYG``````````QB;W1T;VU/=71S971L;VYG``````````MR:6=H=$]U='-E
M=&QO;F<``````#A"24T$*```````#`````(_\````````#A"24T$%```````
M!`````(X0DE-!`P``````]<````!````H`````\```'@```<(````[L`&``!
M_]C_[0`,061O8F5?0TT``?_N``Y!9&]B90!D@`````'_VP"$``P("`@)"`P)
M"0P1"PH+$14/#`P/%1@3$Q43$Q@1#`P,#`P,$0P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P!#0L+#0X-$`X.$!0.#@X4%`X.#@X4$0P,#`P,$1$,#`P,
M#`P1#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#/_``!$(``\`H`,!(@`"
M$0$#$0'_W0`$``K_Q`$_```!!0$!`0$!`0`````````#``$"!`4&!P@)"@L!
M``$%`0$!`0$!``````````$``@,$!08'"`D*"Q```00!`P($`@4'!@@%`PPS
M`0`"$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R624_#A\6-S
M-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3TI;7%U>7U
M5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0`"`@$"!`0#!`4&!P<&!34!``(1
M`R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E!A:BLH,'
M)C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E]59F=H:6
MIK;&UN;V)S='5V=WAY>GM\?_V@`,`P$``A$#$0`_`/3;"=YU_P!842[:"YSH
M:!)),``*5@]Y_P!>R':&NJ>VP?HRTA\F/:1[O<DI`_JF$R?TTP"9`<6Z?RP$
M'[=9?7NJM&P_G,X_SE#[)TULQ:W@Z.>T_BXHM3&M8!7!9XAS2/RIVC'Z^M#^
MZ@)N)DO<?/<?[U'?9^\[[RK):T\Q]X_O436WQ`^);_>E:.$H6VVMU;8X?VBC
M595Y>UI.X$@3P=?@H;`#^;\=S?\`R25#G/N8W8YON'N=M`T/]=)`)!&[?VO\
M2/FB2?$I0?\`6$H/^I":S*D^)2D^)2@_ZD)0?]2$E,)=W)0KB37!)Y'!(138
M9AK'./R`_P`YQ0+SN86VUCTR1KO`U[:HH)%-2]P!&QVNNX@G\=4/>_\`?=_G
M'^]&./0[Z%NSR>6D?YS'(;Z'M_.8X>+7M_B6HV&$B6]?8P+G$07.(\"3_>AF
MEI(.ZP002&O=!\HW(S*G/,$M:/$N;_Y)';BT?GV@_!S1_%&Z5P&73[6>-ETV
M7G&JW,>&EVPB!&G#@?-71N`U)/S5/&Q\*O*-E3@_(+8C>"0W28K"NP?]8337
M1ECQ5ZJWZ=G_V0`X0DE-!"$``````%4````!`0````\`00!D`&\`8@!E`"``
M4`!H`&\`=`!O`',`:`!O`'`````3`$$`9`!O`&(`90`@`%``:`!O`'0`;P!S
M`&@`;P!P`"``0P!3`#8````!`#A"24T$!@``````!P`(``$``0$`_^$-UFAT
M='`Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\`/#]X<&%C:V5T(&)E9VEN/2+O
MN[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC.60B/SX@/'@Z>&UP;65T
M82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX;7!T:STB061O8F4@6$U0
M($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+"`R,#$R+S`R+S`V+3$T.C4V.C(W
M("`@("`@("`B/B`\<F1F.E)$1B!X;6QN<SIR9&8](FAT='`Z+R]W=W<N=S,N
M;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN<R,B/B`\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(B!X;6QN<SIX;7`](FAT='`Z+R]N<RYA9&]B92YC
M;VTO>&%P+S$N,"\B('AM;&YS.GAM<$U-/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C`O;6TO(B!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87`O,2XP+W-4>7!E+U)E<V]U<F-E179E;G0C(B!X;6QN<SID8STB:'1T
M<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B('AM;&YS.G!H;W1O<VAO
M<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W`O,2XP+R(@>&UP.D-R
M96%T;W)4;V]L/2)!9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@>&UP
M.D-R96%T941A=&4](C(P,34M,#,M,#14,30Z,3(Z,C$K,#@Z,#`B('AM<#I-
M971A9&%T841A=&4](C(P,34M,#,M,#14,30Z,3(Z,C$K,#@Z,#`B('AM<#I-
M;V1I9GE$871E/2(R,#$U+3`S+3`T5#$T.C$R.C(Q*S`X.C`P(B!X;7!-33I)
M;G-T86YC94E$/2)X;7`N:6ED.C,Y,D(X.#5!,S5#,D4T,3$Y,#=&0S!&044Y
M-S$P1C="(B!X;7!-33I$;V-U;65N=$E$/2)X;7`N9&ED.C,X,D(X.#5!,S5#
M,D4T,3$Y,#=&0S!&044Y-S$P1C="(B!X;7!-33I/<FEG:6YA;$1O8W5M96YT
M240](GAM<"YD:60Z,S@R0C@X-4$S-4,R130Q,3DP-T9#,$9!13DW,3!&-T(B
M(&1C.F9O<FUA=#TB:6UA9V4O:G!E9R(@<&AO=&]S:&]P.D-O;&]R36]D93TB
M,R(@<&AO=&]S:&]P.DE#0U!R;V9I;&4](G-21T(@245#-C$Y-C8M,BXQ(CX@
M/'AM<$U-.DAI<W1O<GD^(#QR9&8Z4V5Q/B`\<F1F.FQI('-T179T.F%C=&EO
M;CTB8W)E871E9"(@<W1%=G0Z:6YS=&%N8V5)1#TB>&UP+FEI9#HS.#)".#@U
M03,U0S)%-#$Q.3`W1D,P1D%%.3<Q,$8W0B(@<W1%=G0Z=VAE;CTB,C`Q-2TP
M,RTP-%0Q-#HQ,CHR,2LP.#HP,"(@<W1%=G0Z<V]F='=A<F5!9V5N=#TB061O
M8F4@4&AO=&]S:&]P($-3-B`H5VEN9&]W<RDB+SX@/')D9CIL:2!S=$5V=#IA
M8W1I;VX](G-A=F5D(B!S=$5V=#II;G-T86YC94E$/2)X;7`N:6ED.C,Y,D(X
M.#5!,S5#,D4T,3$Y,#=&0S!&044Y-S$P1C="(B!S=$5V=#IW:&5N/2(R,#$U
M+3`S+3`T5#$T.C$R.C(Q*S`X.C`P(B!S=$5V=#IS;V9T=V%R94%G96YT/2)!
M9&]B92!0:&]T;W-H;W`@0U,V("A7:6YD;W=S*2(@<W1%=G0Z8VAA;F=E9#TB
M+R(O/B`\+W)D9CI397$^(#PO>&UP34TZ2&ES=&]R>3X@/"]R9&8Z1&5S8W)I
M<'1I;VX^(#PO<F1F.E)$1CX@/"]X.GAM<&UE=&$^("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@("`@
M("`@("`@("`@/#]X<&%C:V5T(&5N9#TB=R(_/O_B#%A)0T-?4%)/1DE,10`!
M`0``#$A,:6YO`A```&UN=')21T(@6%E:(`?.``(`"0`&`#$``&%C<W!-4T94
M`````$E%0R!S4D="```````````````!``#VU@`!`````-,M2%`@(```````
M````````````````````````````````````````````````````````$6-P
M<G0```%0````,V1E<V,```&$````;'=T<'0```'P````%&)K<'0```($````
M%')865H```(8````%&=865H```(L````%&)865H```)`````%&1M;F0```)4
M````<&1M9&0```+$````B'9U960```-,````AG9I97<```/4````)&QU;6D`
M``/X````%&UE87,```0,````)'1E8V@```0P````#')44D,```0\```(#&=4
M4D,```0\```(#&)44D,```0\```(#'1E>'0`````0V]P>7)I9VAT("AC*2`Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY``!D97-C`````````!)S4D="
M($E%0S8Q.38V+3(N,0``````````````$G-21T(@245#-C$Y-C8M,BXQ````
M````````````````````````````````````````````````````````````
M``!865H@````````\U$``0````$6S%A96B``````````````````````6%E:
M(````````&^B```X]0```Y!865H@````````8ID``+>%```8VEA96B``````
M```DH```#X0``+;/9&5S8P`````````6245#(&AT='`Z+R]W=W<N:65C+F-H
M```````````````6245#(&AT='`Z+R]W=W<N:65C+F-H````````````````
M`````````````````````````````````````````````&1E<V,`````````
M+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@``````````````+DE%0R`V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@````````````````````````````!D97-C````````
M`"Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M```````````````L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0``````````````````````````````````=FEE=P``````
M$Z3^`!1?+@`0SQ0``^W,``03"P`#7)X````!6%E:(```````3`E6`%````!7
M'^=M96%S``````````$````````````````````````"CP````)S:6<@````
M`$-25"!C=7)V````````!``````%``H`#P`4`!D`'@`C`"@`+0`R`#<`.P!`
M`$4`2@!/`%0`60!>`&,`:`!M`'(`=P!\`($`A@"+`)``E0":`)\`I`"I`*X`
ML@"W`+P`P0#&`,L`T`#5`-L`X`#E`.L`\`#V`/L!`0$'`0T!$P$9`1\!)0$K
M`3(!.`$^`44!3`%2`5D!8`%G`6X!=0%\`8,!BP&2`9H!H0&I`;$!N0'!`<D!
MT0'9`>$!Z0'R`?H"`P(,`A0"'0(F`B\".`)!`DL"5`)=`F<"<0)Z`H0"C@*8
M`J("K`*V`L$"RP+5`N`"ZP+U`P`#"P,6`R$#+0,X`T,#3P-:`V8#<@-^`XH#
ME@.B`ZX#N@/'`],#X`/L`_D$!@03!"`$+00[!$@$501C!'$$?@2,!)H$J`2V
M!,0$TP3A!/`$_@4-!1P%*P4Z!4D%6`5G!7<%A@66!:8%M07%!=4%Y07V!@8&
M%@8G!C<&2`99!FH&>P:,!IT&KP;`!M$&XP;U!P<'&0<K!ST'3P=A!W0'A@>9
M!ZP'OP?2!^4'^`@+"!\(,@A&"%H(;@B"")8(J@B^"-((YPC["1`))0DZ"4\)
M9`EY"8\)I`FZ"<\)Y0G["A$*)PH]"E0*:@J!"I@*K@K%"MP*\PL+"R(+.0M1
M"VD+@`N8"[`+R`OA"_D,$@PJ#$,,7`QU#(X,IPS`#-D,\PT-#28-0`U:#70-
MC@VI#<,-W@WX#A,.+@Y)#F0.?PZ;#K8.T@[N#PD/)0]!#UX/>@^6#[,/SP_L
M$`D0)A!#$&$0?A";$+D0UQ#U$1,1,1%/$6T1C!&J$<D1Z!('$B8211)D$H02
MHQ+#$N,3`Q,C$T,38Q.#$Z03Q1/E%`84)Q1)%&H4BQ2M%,X4\!42%3055A5X
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M-C<V<C:N-NDW)#=@-YPWUS@4.%`XC#C(.04Y0CE_.;PY^3HV.G0ZLCKO.RT[
M:SNJ.^@\)SQE/*0\XSTB/6$]H3W@/B`^8#Z@/N`_(3]A/Z(_XD`C0&1`ID#G
M02E!:D&L0>Y",$)R0K5"]T,Z0WU#P$0#1$=$BD3.11)%546:1=Y&(D9G1JM&
M\$<U1WM'P$@%2$M(D4C721U)8TFI2?!*-TI]2L1+#$M32YI+XDPJ3'),NDT"
M34I-DTW<3B5.;DZW3P!/24^33]U0)U!Q4+M1!E%049M1YE(Q4GQ2QU,34U]3
MJE/V5$)4CU3;52A5=57"5@]67%:I5O=71%>25^!8+UA]6,M9&EEI6;A:!UI6
M6J9:]5M%6Y5;Y5PU7(9<UETG77A=R5X:7FQ>O5\/7V%?LV`%8%=@JF#\84]A
MHF'U8DEBG&+P8T-CEV/K9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL
M:4-IFFGQ:DAJGVKW:T]KIVO_;%=LKVT(;6!MN6X2;FMNQ&\>;WAOT7`K<(9P
MX'$Z<95Q\')+<J9S`7-=<[AT%'1P=,QU*'6%=>%V/G:;=OAW5G>S>!%X;GC,
M>2IYB7GG>D9ZI7L$>V-[PGPA?(%\X7U!?:%^`7YB?L)_(W^$?^6`1X"H@0J!
M:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B`2(:8C.B3.)F8G^
MBF2*RHLPBY:+_(QCC,J-,8V8C?^.9H[.CS:/GI`&D&Z0UI$_D:B2$9)ZDN.3
M39.VE""4BI3TE5^5R98TEI^7"I=UE^"83)BXF229D)G\FFB:U9M"FZ^<')R)
MG/>=9)W2GD">KI\=GXN?^J!IH-BA1Z&VHB:BEJ,&HW:CYJ16I,>E.*6IIAJF
MBZ;]IVZGX*A2J,2I-ZFIJARJCZL"JW6KZ:Q<K-"M1*VXKBVNH:\6KXNP`+!U
ML.JQ8+'6LDNRPK,XLZZT);2<M1.UBK8!MGFV\+=HM^"X6;C1N4JYPKH[NK6[
M+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#`[,%GP>/"7\+;PUC#U,11Q,[%2\7(
MQD;&P\=!Q[_(/<B\R3K)N<HXRK?+-LNVS#7,M<TUS;7.-LZVSS?/N-`YT+K1
M/-&^TC_2P=-$T\;42=3+U4[5T=95UMC77-?@V&38Z-ELV?':=MK[VX#<!=R*
MW1#=EMX<WJ+?*=^OX#;@O>%$X<SB4^+;XV/CZ^1SY/SEA.8-YI;G'^>IZ#+H
MO.E&Z=#J6^KEZW#K^^R&[1'MG.XH[K3O0._,\%CPY?%R\?_RC/,9\Z?T-/3"
M]5#UWO9M]OOWBO@9^*CY./G'^E?ZY_MW_`?\F/TI_;K^2_[<_VW____N``Y!
M9&]B90!D0`````'_VP"$``$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0$"`@("`@("`@("`@,#`P,#`P,#`P,!`0$!`0$!`0$!
M`0("`0("`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#`__``!$(`$("RP,!$0`"$0$#$0'_W0`$`%K_Q`#<``$``00#
M`0$`````````````!0,$!@<!`@@*"0$!``(#`0$!``````````````0%`0(#
M!@<($``!`P("`P<)%04$"`8#```!``(#!`41!B$Q$D%189&2$P=QT2(RTQ14
M%96!H;%28H*R,U.3-'24-=46-E:6%PA"(T/457(E176BPM)C<[,D-^&#M7:&
MUE>7&!$``@$"`@4&"0@(!`8#``````$"`P01!2$Q49$206&AT3(&<8&QP4*2
M$Q05(M(S4Y,T5%7A4F)R0W,U!_#Q@A:RPB.STY2#1'3_V@`,`P$``A$#$0`_
M`/OINDLD%NK9H7F.6.FE?&\`$M<UI(<`X%I(.^$!K7Q]>/#Y>1!W)`/'UX\/
MEY$'<D`\?7CP^7D0=R0#Q]>/#Y>1!W)`/'UX\/EY$'<D`\?7CP^7D0=R0#Q]
M>/#Y>1!W)`/'UX\/EY$'<D`\?7CP^7D0=R0#Q]>/#Y>1!W)`/'UX\/EY$'<D
M`\?7CP^7D0=R0#Q]>/#Y>1!W)`/'UX\/EY$'<D`%^O)T"OE)W@R#N2`B;YFN
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MFO:2"8J^VVM[=&XUU/1T[F`^:M96E"7HX>`Z4L\S.D\?;*:V2BO-@9O;_P!2
MN8SLMN\54TZ-J>UOHG-X3WO4TN('`'*/*P?H5=_Z"UH]YD]%S:8<\'YGUF<V
M_ISI[B6M9FZ:CE=A^ZN-+3TAQ/[/..IGPGE*-*VKQTN&*YBVHYUEM;0KCA>R
M2:Z=729C!G7,-4P24M^=4QD8A]/WA.W#?QB@<%Q::T-8,LXRC47%3DI1YFGY
M"I];\SC7>*CWFD_EE@R/KAF;^L5'O5'_`"R`?7#,W]8J/>J/^60#ZX9F_K%1
M[U1_RR`?7#,W]8J/>J/^60#ZX9F_K%1[U1_RR`?7#,W]8J/>J/\`ED`^N&9O
MZQ4>]4?\L@,EMN8[Y-2,DEN4SWESP7&.G!P#R!VL(&@("^\?7CP^7D0=R0#Q
M]>/#Y>1!W)`/'UX\/EY$'<D`\?7CP^7D0=R0#Q]>/#Y>1!W)`/'UX\/EY$'<
MD`\?7CP^7D0=R0#Q]>/#Y>1!W)`/'UX\/EY$'<D`\?7CP^7D0=R0#Q]>/#Y>
M1!W)`/'UX\/EY$'<D!;SYGNM/AM5T[B['`!D`U;I)BWT!'.S??CH96N8/^%`
MX\9A&E`4/K3F'^JS^]4O\N@'UIS#_59_>J3^70#ZTYA_JL_O5)_+H!]:<P_U
M6?WJD_ET`^M.8?ZK/[U2?RZ`Y;FG,)<T&ZSX$C^%2[_Q=#*UH\L7/IBZ3X+E
M<88\YW&.&&OK8HF"CLN#(XZJ5D;`76MQ(:QH&DXJXA;T7"+]FL<%MZSY[7S;
M,HW-Q"-Y)0C-X:(ZL7S%K%TQ=*\S@V'.%VF<=R.@LS_8VDK+M[=:Z<5OZS2.
M:YK-X0O)M\T8O_E+:OS+TY7K&2DZ5,XY;D?VKX*?)\M,P_$JS+51(6C>V\5M
M!V=/1*VA-<_%Y4SA7I=XKSY5'.[JWD^5>R:]65-OI,2K+C^I:T05%QK?U&YA
MN=!3#G):>@RQDV@K&0X@%[I:C+TT;RTG3L`'=7=5,NFXQAEL8R>V4FO*5=6Q
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MI>^_ET^0V'Z(6/=+;ZE=/6/C^<_F$]T/FD/<NEWICN`)@Z5\VVF7#L74%)E-
M\0/#3U>6YP[A[);PM[6.NVA)<_%YF1;C-,[KKY&>7%*6V*I8;I4WY3`+ETE?
MJHAVGV?IZN-<T:H;C8,IT4YW@)H<N2PD]4!2H4LK?TE@EX')^<HKB\[]1Q=I
MWLE-;)4Z47O5-HP"Y]/?ZQ;3M&JZ0,T2Q-QQGH+/DZOAP&[M4^7'/`PWVA28
M6>2SU48)\[DO.4=SWA_N/:XNIF5=QVQA1DNBGCT&'O\`U<_J6B>8Y>EN_P`4
MC3@Z.6RY2B>#JP+),M-<#BI'PG+7JM([Y?.*I]_>^46XRSZLI;'"DO+3'_\`
M77ZE?_R[??(^4/\`ZVGPG+?PD=\NLQ_OWOE^?U?4I?\`C!_5W^I4`D]+M]P`
MQ/\`<^4-0_\`C:?"<M_"1WRZQ_O[OE^?U?4I?^,]%9*OGZVLXVVW7J7IF^K5
MGNE-#6T=1<Z#*M97344[0^&=MNH<LDQ\[&0YHDD:<#I`53<SR.WE.FK)SJ1>
M#P<DL5KTN1]`R>T_NCF]O;WDN\D;>TJQ4HN:I2DXO4^"-/1BM*Q9Z"R]2=+U
M#S<N:/U#=(.8YVX%]/;K-D:P6\G''9#FY8JJQ[>JX'!5=6YMI-JCEU*$>=RD
M_P#BP/>6&1YS1X99EWQO;B>R$*%*/_;E+I-KQ9YSC%&R,9CN$H8T-$D\5MDF
M?A^U*]MOC:]YW2&M'`H3C%MOA1ZB$JD(QC[63P6MX-^-X+%^(G;7G7-<T<QF
MO=3(6R-#2Z"A&`V<<!LT@W5RFDG@D2:,I2C)R>+Q)49OS,TX^-I3P.@HRWB%
M."M#L7D>=[X-$U2]W#&V!A/F&`A`25-FZXU+MAE?4-?@3LOB@U#7@YL9:<!U
M$!>^/KQX?+R(.Y(!X^O'A\O(@[D@'CZ\>'R\B#N2`__0^^6]?--Q^*3>P*`U
M$@"`(`@"`(`@"`(`@"`Y`)(`&).H(##;OG[*MEEDIZFY"IJHB1)2V^,UDC'#
M06/?&1`QX.X7KO"VK5%BH8+GT%9<YQE]K)PG7XJBY(KB_1TF`W#IE:-IMHL1
M=Z6>YU.R.`][TH)PX"]28V'Z]3<5%7O,M*M[3QR?F768+<>DC.5R#F^-&VZ)
MVCFK73QTN`WN?(?.3PXJ1&UH0U1Q?/I*JMG>9U\5[QP1?)!8=.LUOF"HJ*NE
M=)65-15R&6,F2KGDJ'%Q)TXRN=@>HI"2BL(I)<Q5SG.H^*I.4I<[;\IAZ&H0
M!`$`0!`$`0!`$`0!`$`0%:FJJJB>):*JJ:*0:0^DGEIW8\/-N:#YJPTI:))/
MPF].=2D^*E4E&7,VO(9M;NDO.-OV6NN,=RB;@.:N=/'.<-X3L$<PXRH\K2A+
MT<'S%I1SS,Z."==3CLDL>G69S;^F2%VRV[6.2,Z-J:VU#9&<)YBIV7^8'J/*
MQ?H5-Y:T>\T7@KBT:>V+\SZS/[/GG*][ECIZ2YLBJY2!'25S'4<TCC^Q&9?W
M4C\=P..*C3MZT$W*&CFTEQ;9M874HPIUTJCU*7R7XL='29<002"""-!!T$'>
M(7$L3A`$`0!`9=:?@,?]J3_F.0$D@"`(`@"`(`@"`(`@"`(")N7;Q?V7>B$!
M&H`@"`(`@*9E8-W'@&G_`,$!T$_9#9;NC7U=Y`M#Q-`SV*U,KZV=U(V:66MJ
MY7.G<Z4;3ZB1YV6'!H&)T:%9JI/ABN+1@CQT[*V5Q7DZ6,N-O3IUMEXQC(QL
MQ,9$WTL;&L;Q-`"U\)WC&,%A"*2YM!V63)!YF^SE[^(2>S8MZ7TM+PD+,ON-
MW_+?E1Y_&H=0>@K4\(<H`@"`(`@"`(`@"`(`"0<02#OC0>-#/@+&NM5JNC#'
M<[9;[@T@C_JZ2&9VG>E+>='F.68RG#3";3YF<*]M;7*X;FVIU%^U%/IUFOKE
MT0Y,KMIU+!76:5VD.M]4Y\`=O][57.LV>`$*5"^N(ZY*2YUU%'<=U<HKXNG"
M=&7[+T;I8FOKKT(W2)DKK1>J.N;LNV(:Z&2BF.@X#G8^>@Q\P*5#,8-KVE-K
MP:2AN>YUS%2=I>0FL-4EPO>L5Y#]+\@T%5;\AY,HJF+9J*3*]DIYPPB1@EBH
M(6/#7MQ#FAPT'=7D+J:G=7,HZG-^4_1>14*MODN4TJJ^7&VIIX:=*BDS*EP+
M4(#(+-[5/_Q&^P7&IVB5;]F7A\Q,K0[A`2-K^%M_L/\`00&3H`@"`__1^^6]
M?--Q^*3>P*`U$@"`(`@"`(`@"`(`@._-O#=LL?L>FV7;/*PP0S@\,<'@8QG&
M:6#*68YH)'PS1VF<QRQ.+)(RYT<;BQ[<"UQ8\C$;ZZT$G7I)K1Q$#,Y2CEU[
M*,L)*F]*\1X_C`#&@:!L@^:1B2=\DJ[/G"6"P6H[H`@*,\+*B,Q2C%CM8W01
MI:X'<+2@(&:R2@DP2M>-QLG8NY0Q:?.0$=+0UD/;P/PT]DP;;<!CNMQWD!:'
M02#H(UC=0!`$`0!`$`0!`$`0!`$`0!`$!P0",#P'>((U$$:0X'41I"!I/6>P
M\J3SU65\OU%3*^>>:U4KI9I';4DC@TMVGN.ESMEHTZRJ.JDJM1)8+B9])RZ<
MJF7V4YR;FZ:Q;ULGUS)@UZ`"3O`$GB&E`7<5!638%E.\-)'9R?NVX;^+\#AY
MB`DH;)(2#/*UH_:9'V3NIMG!HQZA0$_%$R&-L48V6,&`'HDG=)*`J(`@"`(`
M@"`(`@"`(`@"`B;EV\7]EWHA`1J`(`@"`L7N+B<3C@3AP:=Q`=4!R-8ZH]%`
M:?J_A53\9J/^<]6"U+P+R'F*GT]?]Y^4MUL:A`0>9OLY>_B$GLV+>E]+2\)"
MS+[C=_RWY4>?QJ'4'H*U/"'*`(`@"`(`@"`(`@"`(`@"`X(Q!&_H0&Z,O=+$
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M#`+0[E[%;*N328Q$-&F1V!P(.G9&T4!+4=N[VDYUTFV\`@!HP:,>$DD^<@)-
M`$`0'__2^^6]?--Q^*3>P*`U$@"`(`@"`(`@->YLZ6>C;(TTE+FC-]LM]QC:
MUS[1`)KC=V[;0Y@DH:*.5\+I&G$"0M.'`I%*TN:ZXJ5%N.W4M[*7,>\>193*
M5/,,SIPK+7!8RGZL<</'@:"S#^L7*-+MQ94RE?KZ\8AE9=YH+%1$[CA`.^ZY
M[-WM6E6%/)JKP=6M&/,M+\R/'WG]S<MIMQR_+:U9_K3:IQW:9=!H[,'ZJNE2
M\<XRUR67*L#\0UMJH!5U;`<1HK[D9W;7"UC5.IY59P[2E-\[T;D>3O?[A=X;
MGB5O*E;P_8CC+UI8Z?$C5C>E?I097>,F](.;>_=K;YTW>H<S'>-,3WJ6>IV,
M%*]TM>'A]WAP^`\\N\.?JM[?XS<^UV\;PW:O%@9K6_JGZ4;=E:^4MW=9,T4[
M[9)&\W*@%%6D<Y%B[OVVNAVGZ-;HW+E#*K25:FX*4)8\CQ6YEQ+^X&?T[*YI
M73I7%-PP^5'AER>E'#I1A%A_53E6I$<>9,M7NR/(#75-MD@O-&-`[(QCO:L:
MWUI4JIE558^SJQEX=!7VO?RPJ8*]LJM)[8X37F9NS+/25D/.4C8,MYGM]?6/
M8YXMLG.T5SV8QC(10U<<4K^;&EVQM8#3J4*K:W%'34I-+;K6\]/99WE.8M1L
M[Z$ZGZNJ7JLSA1RS"`(!CAJ0%&6"";VV*-^YBYHQX\,4!'RV>EDQV-N$G=8=
MH#UKL?10%A+9)Q[3+'(-.AX,;MW#3V3<4!'2T-7#CMP28>F:-II&_BW'1U4!
M:ZC@=!WMU`$`0!`$`0!`$`0!``"3@`2=X:3Q!`7<=!62]K3O`(Q#GX,;AACC
MBXC`(#V9D>R3.RCEHS31Q_W32Z(P9#AV6C$[+525UA6JIZ^(^CY7_3;'^6C-
M8K/21]N'S'##LW8#DLV5R)Q(1P0Q#".*-G"UC0>/#$H"J@"`(`@"`(`@"`(`
M@"`(`@"`("RJZ9TY:6.:"T$8.T`XG?W$!&/I:AG;1.(&ZW!XT88]KB=U`6Y!
M&L$=5`$`0%@=9ZI]%`<(#D:QU1Z*`T_5_"JGXS4?\YZL%J7@7D/,5/IZ_P"\
M_*6^YCN#6=P=4K)KS\A%U=\LU!B*NYTD3AKC;()I?,CAYQV*WC3G+LP9&JWM
MG0Q]K<P3V8XO<L3!<PYUMU;;JRVVZ"IG-9%S#ZF=G,0QQES7.>QA)DD>0W`:
M`%)I6\E.,YO!+24E_G%O6H5:%O"4G)88O0EX.5ZC60T:%-/-A`$`0!`$`0!`
M$`0!`$`0!`$`0&I^F9K79.8UP#FF\T&(<`0>PJ=8.@J98?>/]+/,=[M.413U
M>VCY&>:;7<[K8IVU-CNMSLU0UP<V6UU]50N!!QU4\K&'S0K><(55PU(1DN=)
MGSRVN;FRFJEE<U*,URPDX^1H_53]%F:LR9VR?G:JS?>:S,53:<S6NAMU1<S'
M--34<UH?/)!MMC890^8;1+]IV.ZO'9[0HV]Q15"FHIP;>&W$_17]K,WS/-\L
MS2>9WLZ\Z=>,8N6EI.&.&/+IVGM-H#1@T!HWF@`>=@J,^HG*`(`@"`(#_]/[
MY;U\TW'XI-[`H#42`(`@"`(`@`0+6C\ENGAK1TR](Q#0"[,&D@#$_P!W4&LZ
MRO76/W*V_=\Y^<>]J7^Y\[?+[;_EB:F4D\\$!P2!K('5T(8QPUEA>K;<;E8;
MQ#;J"LKII*&1K(Z6GDF+G%\>#06MV03PD+>G.$*M-SDDL3%2A7N+>O&A0G.7
M#R)LUY:NAS/=Q#'3T=%983A^\NM6WG<,,3_TM+S\F(X2%*G?V\<<&Y/F7G9!
MM^ZV;U\'.G"E';-Z=RQ9Z"Z'>A6CL>?<M7>XWZ:X5M'45+XZ>BHV4M("^AJ8
MW-=-,Z2H>W!QU`:577N82G0JPA3PBURO%Z]Q[+NUW3I6N;65Q7O93J1D\%%)
M+3%K6\6>[FV2V-`;WN78;KY)"3U3M!47M:GZQ]95A:+^%CX6SI)8;<\=BR2(
M[\<KO0?M`HJTUK>)K++[66J+B^9]9&39:D&)IJMKAN,GC+3RV$CSENJZY8D6
M>5R_A5D_#UHBIK1<8,2ZE<]HT[<)$K<.$-[(<2Z*I!^EI(D[.YIZZ3:YM)'.
M!8[9>',=Z5S2T\1`6^O417HUZ`@"`X0%&2F@E!$D,;\=]HQY6L("PEL]))CL
M<Y"[<V7;31ZUV/HH"/ELE0T_NI8I1O.QC=P:3B,4!'R457%I?!(`-;FC;:,/
M5-Q"`M<,-!T%`$`UG`:3O;J`NXZ"KE[2!^&^\!C>#2XC%`2$=CF)!EFCC&\P
M%[CIU8G9`0$A%9Z2/`O#YCZMQ:WDLP]%`7\<$,0`CBC8!JV6@'CPQ*`JNU'J
M'T$!Z\R7]D,M?Y13?ZRI;G[Q6_>/H^5_TRQ_EHR9<2<$`0!`$`0!`$`0!`$`
M0!`$`0!`$`0!`='1L>,'L:[J@%`6SZ&!VH%A]2='$<0@+5]N</:Y`X:=#@6G
M@U8C!`0CX)6N(+"=)U$'=.\@.C8I':F.ZI&`XS@@*\=*]SFAQ#<7`;YUC>T(
M96EI'CG,&>;RVZW2EI(Z2DCI[C7P-D$;IYGB*KEC#RZ4[#2[9QPP."OJ5M!P
MA*3;;2\A\MO<ZNU<W,*4802J26UZ&URF$5=WNE>3WY<*N<']ATSFQC@$4>PP
M#S%)C3A'5%%/5NKFM]+7D_'HW+01P`&H#BT\:W(YR@"`(`@"`(`@"`(`@"`(
M`@"`(`@"`U1TR?8]G^<T'L*E3+#[Q_I9YGO=_28_SH>1GEM71\U/U"_0)]B.
MD?\`]X6?_P!"D7D>\?WFW_<?E/O_`/9O^E9W_P#JA_VV>\UYT^Q!`$`0!`$!
M_]3[Y;U\TW'XI-[`H#42`(`@"`(`@"`\'=,WZ=ND"_9VS-G++C[+>:"_5HN+
M+>:]MNNM(>]:>!].Z*L#::I(=!BUS9&[0.H*^L\RMX4*5"KC&45ACK7^/$?(
M>\_<C.KS-;_,[#V=6C6GQ</%PS6A)K!Z'JY&>?9.ASI#I#_>U@J+)&"09K@"
M8]!()::05#7MT:\1BK!7EM+L55)\WZ3Q[[JYY3>%S9.C';+]&),4'170C!UR
MO,]21VT-!$RG9CNM,LQEE\X+65T_1IZ.<G4.Z]+0[B\<GL@L%O>+,SH<F97M
MVRZGM$$DC?XU87UDF._^^)C!]:N$JU62P<WAS:"YH9-EMNTX6J;VR^4^DE;E
MS<-LK&1B.)HIW!K(VMC;K;@`Q@:/.7-:9)\Y,J\,*$XQ22PU+08I0V.\W/#O
M"UUU2T_Q&0/;%YLL@9&!YJ[2J0AVI(@TK2ZK_0V\Y>+1O>@V7E#(M\MUXH;O
M<>]*6&D,C^]A-S]5(Y\+X@TB(&*,`OQ)+CJ46M7IS@X1Q;9>9;E5U0N:=Q6X
M8QCCHQQ;T8<F@W(HAZ0(`@"P"G)%%,-F6*.0;TC&N]$$K*;6IF)0A-83@FN=
M$7-8K;-CLQ/IW''LH)"T`G=V';35T56:>EXD2IE]K/2HN+YGYB*FRU*,33U3
M'C3@V=A8X[PVF;3?.6ZKKTH[B)/*Y+Z.LGX5ATD5-:;C!I?3.>-UT)$K?]`E
MWG+HJD'JD0YV=S33;I-KFTD>[%IP>"P[SP6GB=@MR,]#P:P80!`$!1DIX)?;
M(8W\+FC'C&!0%#Q=0X@][1Z-0[/#<]5P("O'!#%[7%&S#5LM`/'K0R5D,!`$
M`0'!U'J'T$!Z\R7]D,M?Y13?ZRI;G[Q6_>/H^5_TRQ_EHR9<2<$`0!`$`0!`
M$`0!`$`0!`$`0!`$`0!`$`0!`0+^W=_:=Z)0'5`<@D$$:P01U1I0:CS+G3H7
MO+[G6W7+$\%QI:^HFK)+=5S-I:ZDFJ)'2S1PS/P@JX#(XEF):]H.!Q5M;W]-
M0C"LFFEACK3ZCP6:]U;IUZMQE\E.G-N7"WA)-Z7@]36.K4T::NN6,R60D7:Q
M72B:-<LE)(^#JBHA$L)'KE/A6I5.Q4BWX3R]QE]_:-JYLZD%MP>&]8H@6O8[
MM7-)W@1B.J-8*ZD--/4SL@"`(`@"`(`@"`(`@"`(`@"`-[-P8P&1Y.`9&"]Y
M.\&L!.*>%A?*>$=+YC(*/*N8JX;4%IJ@PZ0^<-IFGJ<^YCCQ+C*XHPT.HL2?
M1RR_KZ86LL-KT>7`XK,JYBH6[=1::HLW7P-;4M'5YASRWS0L1N*,W@JBQ%;+
M+^@FYVLL-JT^3$TITL6^XW++,5#;;;<;E7/O=O:RBH*&JK*MQV:D8"GIXI)?
M.5C93A&LY2FE'A>EM(\=WIHUZ^6PHT*$YUO;Q^3&+E+4^1)LQ;*?Z5NG3-IA
M?%DN7+M%-LGQCFZJALD,<;L/WII'F6YR-:#CLMAQ*D5LXR^CBG7XI;(K'IU%
M/EW]O.]V9<#CE;H4GZ5:2II<^&F3]4_4+H&Z%J#H0R?46"*[R7Z]7JO9=\QW
M81.I:*6OCIA2P4MKHW%TD%!108M:YY,DKB7.PT`>2S&_EF%=5'#AIQ6$5RX;
M6]K/T!W/[JT>Z>63LXW+K7=6?'5GAA%RPP2A'DC%:%CI>MF[5`/5A`$`0!`$
M!__5^^6]?--Q^*3>P*`U$@"`(#ASFM&+G!HX2`@+=U7"W42X^I!XL3@$!;NK
MG?LQ@;VT2?.&"`MW5$SM;R.!O8^AI0%$DG222=\DD\9TH!B0",=!UM.EIX"T
MX@A!S<ACURRGEB[XFX6*WRO=KFBA%+4=42TW-.QZN*ZPK58=FH_*0J^76%SC
M[:T@WM2X7O6!B@Z)LH<_SI%V,6./>IKSS7]GG.;YXM]<NOOE?##1CX"O_P!N
M9;Q8XU>'9Q>?#$FJC*F6;1:+B;=8[?!(VD?A.^$5-1B"S3SU3SKL=&Y@M(UJ
MTZD>.JVL25/+[&VMJOL+2">&O#%[WB8%B2`"=`U#4!U`-`4LJ<7@CA`$`0!`
M$`0!`$`6`4Y(H9ALS112C>D8U_GD8K*;6ILQ*,)IJ<%)<Z(J:PVV4DMC?3N.
M[#(0T?\`EOVFKHJLURXD.>7VT]*BXOF?F(N;+<HQ-/4LDWFS,,9/!M,VF^<M
MU77I1(D\KDL73JIK8T14UJN$&)?3/<T:WPX2M\W9[(>:%T52#]+21*EI<T\6
MZ3:YM/D(_?!Q!&@@@@@[Q!T@K<C;5RA`$`0!``"=0)ZB&0A@X.H]0^@@/7F2
M_LAEK_**;_65+<_>*W[Q]'RO^F6/\M&3+B3@@"`(`@"`(`@"`(`@"`(`@"`(
M`@"`(`@.0USC@T%QWF@D\0TH->HL+G=;39873WFZVVTPM:7%]QK:>DT`8D[$
MLC9#HX%M"$ZCPIP<GS(XU[BVM8N=U<4Z</VI)?I->5F?<MPXOIZJ2X;?9QFB
MA<^*1KQM,<V>3FX]ES3B"NBMZKUK#PD*IF]C%)PJ.>*T<*T;V8Q4])4Y)%%:
M86MW'U=0][B.%D(8T<9756J]*;($\]G_``K9)<[Q\A;,Z2;H'`R6RWO;NACZ
MF-WF$O<%M[M#]9G..>7"[5"#7C)ZCZ1K7+@*ZDJZ)QUOC#:J('UA9*!ZTKG*
MVFNS),FTL[MY?2TY0>]=9EU#F&RW`;%'=:20O`Q@DE$+R2.U=!.&$G@P*XRI
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MF\+JSJ0YW%X;UBB$:]C^U<UV_@0<.KAJ70BIIZF=D`0!`$`0!`-;@T!SGN[5
MC&N>\]1K07%8&MI+2R?H<K9BN(:ZFM-4V-W\6I`I(AP[4Y82#P!<I7%&#PE4
M6.\GT<LO[CZ.VDH[7\E=)EU%T8W"3`W"XTU*-&,=,Q]3)PC;=S<0/*"C2OH+
ML0;99T>[M9X.O<1BMD5B]^A&6T'1WER`MYZ&LNDHPQ;/,[F]K_@4P8T@'<*C
MSO*\M":CX"THY#80PXH3JRYWHW(S^W99-,UK:"T4UO81H<(8J<X<+R#*3BHL
MZKEIG-MEW0RYTTE0M8PCX$OTF019=D=IJ*H#'6(FESNIMOP'G+DYKD1.C8-_
M25=WZ24ALENA()B=,\:G3/<[_1:6M6..6G22(6="&GA;?.3-(XTCR^D#:1Y;
M@9*9C(9"-&@R1M:]PZI*TUZV2HI0>,(I/F23WZR49<ZH'LW-ETXDR#LCHW7`
M@E`7D=TC.`DC<WA:0X8]30<$!>1U=-)VLS`?2N.P[S`[#%`7'"-(WP<1QC0@
M"`(`@"`__];[Y;U\TW'XI-[`H#4.(WQQA`,1OCC"`8C?'&$!!2R[;W%T@)Q(
M&+AH`T`#<&A`4]MGIF\H==`-MGIF\H==`-MGIF\H==`-MGIF\H==`-MGIF\H
M==`-MGIF\H==`-MGIF\H==`6]7%'5TM12ND#&U$+XBYI:2W:U.`)P.!`68OA
MDI+D-*D%4A*FW@FC6E7E^YTA=LPBKB&.$M*X/Q&YM1DB1APW,"ID:L)<N#*.
MI97%/'"'%':NHA7_`+H[,H,3AK;*#&[B?@5TT/4R,TUVDT^<Z<['[HSEMZZR
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M-=Z;W@CLAA'])*6/IISW2N9"VYT^8FC`<S74D=9.1J`[YI.;J`3ODE:5+&W:
MQ<>'P/`[VW>/,Z;4?;*LMDEB]ZTGJGH?O.8^E.\26.IL%/EV2&WR7*6Y2W!L
MM.:>&6**5L=`X=^F8\\"T8[.^0JB]A2LX*HJCDL<,,/.>X[N7%WG]R[1VT:,
ME#B<F\5@FD\(Z\=.CD/T!ME#!:;;06NG>Y\%OI8J6-\I;SDC8FX%[]G0'/<2
M<!J7FYR<YRF];9]>MZ,;:A1MX-N$(I+$OL1OCC"U.PQ&^.,(!B-\<80#$;XX
MP@&(WQQA`,1OCC"`8C?'&$`Q&^.,(!B-\<80#$;XXP@&(WQQA`,1OCC"`8C?
M'&$`Q&^.,(!B-\<80#$;XXP@&(WQQA`1UPO5DM$9FN]ZM%IB:W:+[E<J2C['
M?#)Y62.'4!Q6T83F\(0E)\R;.-:YM;9.5S=4Z<?VI)>5XFJ[S^H#HLM!?'!?
MGWZH;B.:L=.Z>(N&YWY4&"F`QW<2%-IY;>3TNGPKG?F//77?'(+;%0NW6GLI
MK%>L\$:GO/ZH9I`YF7LO4%*-.Q4WFX"JD&\324ABBQX#(5,IY0E]+5;\"ZSS
MEUW_`)/%65C"//.6+W1P726]DS'G_I(MLMRKND"ILMM[\GHO%V7:>GH'.,+6
M.>XU$1:X-<),!BYQ6M:-M9S5.-LI3PQQD\3IEU;.N\-M*ZK9S*E;\;CPTHJ.
MK#E7AT:R_INCC)\<G?%PAJ+_`%9TNJK[<)J]SG;YC?((AIX%RE?7#6$&H1V)
M8%A2[MY3"7'6HRKU=M23ET:C/GV.Q5$4>S3Q0AL;&-=2R\SLAC`T-`!+>QPP
MTA1U.:U/$N96-I.*2I):.308_<LM04E+4U=/7XMIHG3.BF#,2QN&($C"WLM.
MZ%TC4;:3CK(-QET:5.I5A5>$5C@^LPT30D8\['I]6WKKL5.*VCGH?=8^6WKH
M,5M.#)`[7)$>$O9B.H<<0@T,DJ._7"W$=XW>HIP-(8VJVHO>I'/9AP8+64(2
M[44SO2NKBCA[*O)+9CHW&64?23=8,&U?B^O:,,7.PII2,=)VX7;!)&^U<96T
M'V<46-+.[J."JQA-;GT&54?278IL&UL510N.M[71U4(/"8RV0#UJXRMIKLM,
MGT\\M9:*M.4'O1EM%F6PW!NQ1WJW3AV@P25,4;CB-3H*@MQXBN4J52/:@RRI
M7MI76%*Y@T^1O#H9$W;).2[[B^XY?M,DKA\*IHVT=3B?VQ/1NB+CNXZ5O"XK
MT^Q5>&S6B-<91E=WBZ]C3<GRI<+WK`UO=.@K+E1M.M%YN-K<>UBJ>:N-.W@)
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M05]14SNDEN$3*:J=`'-%/[?^^9%LZ6@`8JGNZT95<%4Q@ER=)[S(<MN(6:G.
MTX*TI-XR6#PY->G#8;-BL#G8&IK&`Z.QB[,]0O>0/.*A>T7(CT4;"3:=2KNT
M^4DHK-;(^V;SYUXS28CDMV6K7CEM)$+.WCKAQ/G)2-L$0V8FPQ`;D;6-\\:2
MM23%*/9BEX#OMM].WE#KH9&VSTS>4.N@&VSTS>4.N@.['-Q[9NK?'`@*NVST
MS>4.N@&VSTS>4.N@&VSTS>,==`2-LE_ZC8$G8EKB6[6@D#0<,<,0@,@Q&^.,
M(!B-\<80#$;XXP@&(WQQA`?_U_OV?VCNT[4]OVGKO4H"Q\GH!Y/0#R>@.AUG
MYKU[NOS>%`<>2T`\EH!Y+0#R6@'DM`/):`>2T`\EH#LW7_AOK=:PP4)^V'S-
MJ_C]MYG`MEXS2>OT?&4/P^L[S3U!^'TWCU!^'TWCU!^'TWCU!^'TWCU!^'TW
MCU!^'TWCU!^'TWCU!^'TWCU!^'TWCU!^'TWCU!^'TWCU"G+VH^S?;?Q>UU'5
MZI97+VC66K^'XRA^%%GUCG]B/PHGK#[$?A1/6'V)CU1[?+_VS]L=\(]OU_Q?
M]YOKK'4OI/$19]N?W37RZ_'SE'_]6K/VIK_Z9?47;._[=[GP+MO7+67_`,GC
M-Z>O_P"KXB;M_P`)D^RWM3OF_P"$]LWVS_=;_#@N<M7I>,DT/I']#J]'7_D3
M/D]<R8/)Z`>3T`\GH!Y/0#R>@'D]`/)Z`>3T`\GH!Y/0#R>@'D]`/)Z`>3T`
M\GH!Y/0#R>@,?O/MD?V/U#YY]LUGVO@76'+VO$0[KM+Z'_7K+,:A]@]6YJ\S
M@6?7./(ONQS^!$]<?^L2=)[2?LOV[O@GM.H:_5[ZTEKY?&2:/8_AZ_1U?YEU
MY!6N\Z^J=VZO\$];J0RO$</[1WS'J/;]IZ[@0/4]19?A9;;SE]F/PLF\?9C\
M+)O'V8_"R;Q]F/PLF\?9C\+)O'V9T/;M^R>YK[?7^RG)Z1J]?\(F!J'S7J&K
M5JW.!:$H>2T`\EH#M5?!'_-O:GX5\$W>W]2LK6*GT;\^HQG\#KMZY!^P'X'3
MUQ]@7]N^$C[+=J?F[X3K&KU*TGJ]+QG:AV_X?^G63,O;_P"'ZA[;V^KT%S1)
MEKZRGY+0P/):`>2T`\EH!Y+0#R6@'DM`/):`>2T`\EH#LW7_`(9ZW6@.WD]`
+/)Z`>3T`\GH#_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
